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Bovine Leukemia Virus (BLV) is an exogenous type-C 
retrovirus which can induce an aleukemic (AL) stage, a 
persistent lymphocytotic (PL) stage, or a lymphosarcomatous 
(LS) stage in infected animals. After experimental 
infection with BLV, whole blood and serum samples were 
obtained from 12 holstein heifers for 103 weeks and used to 
correlate clinical signs (visual observation and white blood 
cell counts) with changes in humoral immune response (Agar 
gel immunodiffusion using envelope gp50 as primary antigen, 
and ELISA and Western immunoblots using whole BLV as anti­
gen) . Monoclonal antibodies against BLV envelope gp50 and 
gag p24 were produced to confirm reactivity to specific 
proteins for the various assays. To confirm reactivity of 
monoclonals and produce large amounts of selected proteins 
for later studies of BLV, the genes for env, gag, and pX 
were cloned into eucaryotic expression vectors. After 
transfection of appropriate plasmids, correct expression of 
cloned genes was confirmed using monoclonals and indirect 
immunofluorescence for gp50 and p24 and CAT assay for px. 
Total lymphocyte counts indicated 6 cattle reached the PL 
stage during the 103 weeks post infection (PI). Cows 
progressed through three transient disease stages in the 
first 3 months PI: transient eosinophilia, lymph node
x
enlargement and lymphocytosis. Of the 6 cattle 
demonstrating early transient lymph node enlargement, 5/6 
were AL. Changes in the humoral immune response to BLV were 
best detected using Western immunoassays. AL cattle were 
more likely to have an increased antibody response to the 
gag protein p24 early PI as compared to PL cattle. PL 
animals usually reached their highest p24 antibody responses 
after conversion to the PL stage. Antibody response to env 
gp50 increased as a function of time PI regardless of 
disease stage. PL cattle tended to recognize a greater 
number of the lesser gag proteins, pl5, pl2 and plO in the 
first year PI than AL cattle. All cattle decreased markedly 
in their reactivity to any of these lesser proteins after 51 
weeks PI.
Chapter I 
REVIEW OF LITERATURE 
Introduction
The most common neoplasm in cattle is lymphoid leukosis. 
Bovine leukosis exists in two forms based on pathology and 
seroepidemiology: Sporadic Bovine Leukosis (SBL) and En­
zootic Bovine Leukosis (EBL). SBL is generally seen in 
young animals (4 months to three years old), occurs as a 
solitary case in a herd and is noncontagious with no known 
viral etiology. Non-B-cell lineage lymphoid tumors which 
are multicentric, cutaneous, or thymic are seen, usually 
with acute onset (Ghysdael et al., 1984; Olson 1974). EBL 
is a highly contagious disease induced by an exogenous type 
C retrovirus, bovine leukemia virus (BLV) (Deschamps et al., 
1981). It is a chronic disease, with tumors developing in 
only a small number of infected animals over a period of 
years. BLV is related to human T lymphotrophic viruses 
(HTLV-I and HTLV-II) with all three viruses having sequence 
homologies (Burny et al., 1987b; Rice et al., 1987b). They 
possess a unique 31 open reading frame encoding a number of 
viral regulatory proteins, hypothesized to influence the 
progressive stages of malignancy. Pathologically, there is 
an absence of chronic viremia, long latent periods, and no 
preferred site of proviral integration (Burny et al.,
1987b). Because of these common features, it is proposed
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that BLV and HTLV be grouped into a new family of retro­
viruses distinct from the nonacute and the acute (oncogene- 
containing) transforming retroviruses (Rosen et al., 1985). 
This review concerns the development of EBL.
Disease 
Clinical Signs 
Bovine leukemia virus induces three clinical manifesta­
tions in infected cattle. The first is an aleukemic (AL) 
stage in which the BLV infected cow produces a serological 
response to various BLV proteins, but is otherwise clinical­
ly normal. Persistent lymphocytosis (PL), the second stage, 
occurs in 3 0-70% of BLV infected cattle and is characterized 
by a benign non-malignant increase in the number of periph­
eral blood lymphocytes (PBL). The PL stage is characterized 
by an increase in the absolute lymphocyte count of 2.5 or 
more standard deviations above the normal mean as determined 
for that respective breed and age group of animals in two 
successive blood tests (Kenyon and Piper 1977a). In five 
year old Jersey cattle, this would be a lymphocyte count 
greater than 7.5 x 103/ul of blood. This increase in 
circulating lymphocytes, primarily of B-cell lineage, can be 
stabilized for long periods of time, increase, or suddenly 
disappear, with a return to a normal white cell count (Ken­
yon and Piper 1977a? Mikalauskiene et al., 1984; Burny et 
al., 1987b). Finally, a lymphosarcomatous (LS) or tumor 
stage may result primarily in older animals (Marshak et al.,
1967). PL precedes approximately two-thirds of the cases of 
LS (Abt et al., 1969), in which immature lymphoid cells 
circulate, the bone marrow may be invaded, and many organs 
are invaded with cells of lymphoid lineage. Tumors may 
invade mammary glands, subcutaneous tissues, abdominal 
muscles, diaphragm, heart, respiratory tract, and spinal 
cord (Burny et al., 1980; Ferrer et al., 1980). As tumors 
grow, they mechanically impair normal function and generally 
result in a chronically debilitated animal. Enlarged lymph 
or hemolymph nodes may or may not be seen externally, but a 
majority of the cases will have enlarged pelvic lymph nodes 
evident on rectal palpation (Burny et al., 1980; LaBelle and 
Conner 1964).
Infection by BLV is a prerequisite for the production of 
PL or LS stages; however, all infected animals do not 
routinely exhibit these signs. Many animals are clinically 
normal and have lived for greater than 8 years (Olson 1974). 
A large number of studies demonstrated familial aggregations 
of PL and LS cases (Abt et al., 1969, 1976; Ferrer et al., 
1974; Burny et al., 1980; Stear et al., 1987). Abt et al. 
(1969, 1976) also found evidence that PL and LS stages may 
aggregate along different family lines. In 1976, Abt et al. 
conducted a reciprocal foster nursing experiment involving 
114 animals. At the conclusion of the study, of the 80-92% 
BLV positive calves obtained, PL was produced in 88% of PL 
families, 21% of AL families and no PL was produced in
calves from the leukosis-free herds even though 90% became 
infected with BLV. Recent observations in a Shorthorn herd 
suggested that the bovine lymphocyte antigen (BoLa) system 
(inherited in Mendelian fashion) influenced susceptibility 
of resistance to the PL or LS stages (Burny et al., 1987b).
A similar study of dairy cattle in Australia also indicated 
a correlation between BoLa type and disease incidence (Stear 
et al., 1988). Although a strong familial influence in the 
development of EBL occurs, the percentage of LS positive 
cows increases with age, therefore, factors such as virus 
dose, route of infection, age of infection, intercurrent 
disease, or immunologic competence of the host must also be 
considered (Burny et al., 1980, 1985a).
Economic Impact
Available U.S. data indicates a loss of approximately $44 
million due to BLV and EBL. This includes $1.6 million for 
milk production, $40.5 million for replacement of LS cattle, 
$0.5 million for veterinary care and $1.7 million for reduc­
ed foreign trade from semen and embryos (Thurmond et al., 
1987) .
Milk production is not necessarily adversely affected by 
BLV infection. Although LS cows have a substantial drop in 
milk production, many sero-positive cows tend to produce 
more milk than non-infected cows in early lactations (Thur­
mond 1987; Wu et al., 1989). However, Thurmond (1987) found 
longer non-lactating periods and a tendency to produce less
milk in antibody positive cows completing their second 
lactations. Wu et al., (1989), observed sero-positive cows, 
both AL and PL, had a significantly greater genetic poten­
tial and produced more milk than sero-negative animals. The 
genetic potential for fat production was also significantly 
greater for PL cows than for AL or sero-negative cows. 
However, the actual adjusted 305 day fat production was not 
significantly different between groups indicating that PL 
cows did not produce milk fat up to their genetic potential. 
A premium is paid for increased fat levels in milk, there­
fore, this decrease could deleteriously affect the total 
income from milk production.
No significant differences for ages at first calving, 
length of most recent calving interval, mean length of 
calving interval, number of days open, number of times bred 
or incidence of mastitis have been found between BLV sero­
positive versus sero-negative animals (Huber et al., 1981; 
Thurmond et al., 1987). However, Thurmond et al., (1987) 
did find a higher culling rate from a herd for BLV positive 
cows. Salvage value of these culled cows (to be used toward 
a replacement animal) is greatly reduced over that of a 
healthy cull.
Transmission
Transmission of BLV has been studied for over 100 years, 
even before the etiologic agent was known. Early observa­
tions indicated EBL spread by addition of a sick animal to a
herd. Horizontal spread is most common, including trans­
placental transmission, and infected cells are the best 
potential vehicles of spreading BLV (Burny et al., 1980, 
1987b).
A marked increase of BLV prevalence in a herd occurs 
between 1 & 2 years of age, and the percent of positive 
cattle increases steadily with age (Miller and Van der 
Maaten 1980; Burny et al., 1980, Romero et al., 1981; Hugh 
Jones et al., 1984). Most infections occur after calves are 
introduced into the adult herd (Miller and Van der Maaten 
1980). Although rare, calves can be infected in utero as 
evidenced by clinical observation or analysis of precolos- 
tral sera (Piper et al., 1979; Kono et al., 1983; Straub 
1987b). Van der Maaten et al. (1981), found initiation of 
BLV infection during the first, second or third trimester of 
pregnancy had no effect on the number of calves born with 
BLV. Calves can be exposed from infected dams via colostrum 
or milk, especially when these products are contaminated by 
blood (Miller and Van der Maaten 1979; Burny et al., 1980; 
Ghysdael et al., 1984). However, calves from sero-positive 
dams are usually protected against milk-borne or contact 
infection by passively acquired maternal antibodies (Piper 
er al., 1979; Miller and Van der Maaten, 1980). Colostral 
antibodies have a half life of 20 days becoming undetectable 
in most calves by 6 months (Kono et al., 1983; Straub 
1987b). Calves sero-negative at birth are more easily
infected and develop anti-BLV antibodies earlier than calves 
that acquired and then subsequently lost their maternal 
antibodies (Romero et al., 1981). Of importance to man, BLV 
is destroyed by commercial pasteurization (Olson 1974).
There is no evidence to suggest that other excretions or 
secretions of BLV positive cattle could spread BLV. These 
include nasal secretions, saliva, urine and oviductal or 
uterine flush fluids (Miller and Van der Maaten, 1979; 
Ruckerbauer et al., 1988). Zona pellucida-intact bovine 
embryos can be transferred from BLV infected donors, includ­
ing those bred by BLV-infected bulls (Baumgartener et al., 
1978), without risk of transmitting BLV, provided the 
embryos are properly washed before transfer (Burny et al., 
1980, 1987b). However, semen contaminated with infected 
lymphocytes could spread BLV to cattle via contamination of 
the cervical or uterine canal (Hopkins et al., 1988; Straub 
1987b). Roberts et al. (1982) demonstrated BLV transmission 
by the intratracheal, subcutaneous, intradermal, or 
intrauterine routes of infection using 5 x 106 infected 
lymphocytes. BLV could be detected in circulating PBL two 
weeks post infection and two weeks before the appearance of 
detectable serum antibodies, but virus was not found at any 
time in the cell free plasma (Roberts et al., 1985).
The concentration of BLV infected cells in transmitted 
fluids has a great effect on the ability to spread BLV. PL 
cows are much more likely to spread BLV among herd contacts
than are AL animals. Studies have demonstrated almost 300 
times more lymphocytes are needed from an AL cow than a PL 
cow to transmit BLV, with blood volumes ranging from as 
little as 5 ul in a PL cow to 500 ul in an AL animal. (Van 
der Maaten et al., 1981; Roberts et al., 1986; Burny et al., 
1987a). This small amount of infectious fluids tends to in­
criminate biting insects as possible mechanical vectors of 
BLV. This was inferred by Bech-Nielson et al. (1978) who 
demonstrated contact transmission between BLV positive and 
negative cattle was most prevalent during the summer months, 
and BLV infected lymphocytes could be recovered from taban- 
ids allowed to feed on BLV positive cows. Foil et al.
(1988, 1989) demonstrated BLV transmission from a PL donor 
cow to sheep, goats and calves with groups of 20 and 50 
horse flies.
Routine veterinary care, such as vaccinating, tattooing 
and dehorning, is another means of horizontal spread via 
small amounts of contaminated blood (Burny et al., 1987b; 
Hopkins et al., 1988). Hopkins et al. (1988), demonstrated 
colorectal transmission of BLV by gynecological examina­
tions .
In addition to cattle, cases of natural BLV infection 
have been found in sheep, capybara and water buffalo (Burny 
et al., 1987b). One of the first "outbreaks" of Enzootic 
Leukosis in sheep was observed in a flock that had been pre­
viously vaccinated for piroplasmosis using bovine blood
(Miller and Van der Maaten, 1980). Rhode et al. (1978), 
showed virus obtained from both BLV and ovine leukemia virus 
samples, when run on SDS-polyacrylamide gels, were identi­
cal. The ability of BLV to induce leukosis in sheep has 
been confirmed many times using whole blood, tumor cell 
suspensions, cultured lymphocytes or supernatant fluids from 
cultured lymphocytes as inoculum (Van der Maaten and Miller, 
1975b; Kenyon et al., 1981; Rogers et al., 1984; Suneya et 
al., 1984). The most striking difference between ovine and 
bovine leukosis is the increased susceptibility of sheep to 
tumor induction and the rapidity with which it occurs as 
compared to cattle (Miller and Van der Maaten, 1980; Burny 
et al., 1980; Dimmock et al., 1986). From 44% to 100% of 
BLV infected sheep die of LS in a time period ranging from 
15 months to 6.5 years post inoculation (Van der Maaten and 
Miller 1975b; Miller and Van der Maaten 1980; Kenyon et al., 
1981; Ghysdael et al., 1984; Dimmock et al., 1986; Djilali 
et al., 1987b;). Remarkably, contact between sheep does not 
seem to transmit BLV (Straub 1987b). Unlike EBL, sheep do 
not develop a PL stage unless in terminal stages of the 
disease. However, the LS stage is not always preceded by PL 
(Dimmock et al., 1986; Djilali et al., 1987b). Increased 
numbers of PBLs in sheep are observed following BLV infec­
tion. These PBLs are not mature, but consist of 90-98% 
lymphoblasts and, in most studies, signal the impending LS 
stage and death within 1-5 months (Djilali et al., 1987b;
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Rogers et al., 1984). However, Dimmock et al. (1986), found 
prolymphocytes in BLV infected sheep 12-68 wks before death. 
B-cell tumors are most often reported in sheep, though, 
T-cell tumors have also been found (Burny et al., 1985a;
Levy et al., 1987).
Experimental transmission to goats, pigs, rats, rabbits, 
monkeys, chimpanzees and buffalo has been reported (Porte- 
telle et al., 1981; Ghysdael et al., 1984; Schodel et al., 
1986; Straub 1987b; Altanerova et al., 1989). Rabbits in­
fected by BLV die with high frequency of a wasting disease 
reminiscent of immune deficiency (Burny et al., 1985b).
Since the documentation of the transmission of BLV to 
non-human primates, exposure of man to BLV has been a con­
cern. In several surveys, negative results were obtained 
when lab personnel, dairymen, veterinarians and abattoir 
workers potentially exposed to BLV were screened for the 
presence of BLV antibodies. These surveys also found no 
incidence of BLV antibodies in patients with various kinds 
of leukemias or solid cancers (Olson, 1974; Devare, 1980, 
Gilden et al., 1975; Straub, 1987b). Recently, using BLV 
probes and Southern blots, no involvement was shown in 157 
human cases of acute lymphoblastic leukemia and non-Hodgkins 
lymphoma or in 157 matched controls (Bender et al., 1988).
In in-vitro experiments in which BLV was transmitted to 
human B-multiple myeloma cells only 2 of 60 clones screened 
were found positive for BLV by Southern blot, and neither
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cell line produced viable virus or made normal BLV proteins 
(Slavikova et al., 1987). Thus, there is no evidence to 
date that BLV can be transmitted to humans.
The Virus
The morphology of BLV is that of a type C leukemia virus 
(Burny et al., 1985a). It possesses an electron dense core 
surrounded by a lucent area and is enclosed by a double 
layered envelope which sometimes has surface projections. 
Budding of BLV particles from the surface of lymphocytes is 
rarely seen. The particle is 90-110 nm in diameter and 
contains a 60-80 nm core (Weiland et al., 1976). It has a 
buoyant density of 1.15 - 1.17gm/cm3 (Ferrer et al., 1980) 
and has a 70s RNA, that is composed of two 38s dimers 
(Ghysdael et al., 1984). The complete 8714 nucleotide se­
quence of BLV has been determined. It encodes six 
structural and three non-structural viral proteins (Sagata 
et al., 1985b; Rice et al., 1987b). As in all retroviruses, 
it is flanked by long terminal repeats (LTR) and contains an 
RNA-dependent DNA polymerase or reverse transcriptase (Burny 
et al., 1985a). BLV bears some serologic cross reactivity 
to HIV, since rabbit anti-BLV antisera does react with 
cultured lymphocytes of AIDS patients (Thiry et al., 1985). 
However, it bears little homology to any other retrovirus 
except HTLV-I, HTLV-II, and Simian T lymphotrophic virus-I 
(STLV) (Oroszlan et al., 1982; Ghysdael et al., 1984; Burny 
et al., 1987b). These three viruses with BLV may compose a
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distinct family which replicate via trans-activation of 
enhancer-promoter regions of their LTR* s and induce 
pathologic changes in their hosts by similar trans-activa­
tion of cellular genes (Rosen et al., 1985; Sagata et al., 
1985b).
The structural organization and protein-protein interac­
tions of BLV have been determined by both electron micros­
copy (EM) and chemical cross-linking studies (Uckert et al., 
1982; Mamoun et al., 1983b; Burny et al., 1985a). BLV con­
tains an outer membrane composed primarily of glycoprotein 
(gp) gp30-gp50 dimers, which may be linked by disulfide 
bridges. Internal structural proteins exist as homologous 
or heterologous dimers of p24, pl5, or pl2. The two pro­
teins pl2 and pl5 can also complex to RNA.
Coding Potential 
There are three poly-A+ RNA species present by Northern 
blot analysis of BLV-producing cell lines, a full size 9Kb 
mRNA, a 5.1 Kb mRNA and a 2.1 Kb mRNA (Mamoun et al., 1985). 
In vitro synthesis of BLV 38s RNA (9Kb mRNA) produced a 70 
Kd group associated antigen precursor, precipitable by anti- 
p24 antibodies, which contains pl5, p24, and pl2 (core 
proteins) and pl4, (a viral protease) (Ghysdael et al.,
1979; Mamoun et al., 1983a, 1983b). There is a second 45 Kd 
precursor, also precipitable by p24, that lacks the pl4 pro­
tease (Mamoun et al., 1983b; Burny et al., 1985a). The 
smaller polyprotein is not a cleavage product of the larger
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(Ghysdael et al., 1984). The reverse transcriptase-endonu- 
clease protein is made as a third 145 Kd gag-pol precursor 
(Burny et al., 1987b). No information on its cleavage is 
available.
The 24s RNA (5.2 Kb mRNA) is a singly spliced message 
coding for the envelope proteins gp50 and gp3 0 (Mamoun et 
al., 1983b). The glycosylated precursor of gp50 and gp30, 
Pr72env, overlaps the 3' end of pol by 17aa. Gp50-gp30
cleavage occurs at the Arg-X-Arg-Arg sequence found in many 
viruses (Burny et al., 1985a, 1987b). The unglycosylated 
homolog of Pr72env, a 47 Kd polypeptide is not processed 
further, as processing of Pr72env is glycosylation and con­
formation dependent (Ghysdael et al., 1984; Burny et al., 
1987b).
The 16-18s RNA (2.1 mRNA) is a doubly spliced message 
encoding two proteins, pl8 and p38 (Derse, 1987). Ghysdael 
et al. (1979) were the first to demonstrate the presence of 
pl8 from in vitro translated 38s RNA in rabbit reticulocyte 
lysates.
The LTR Region
BLV's 531 bp LTR has been compared to other retrovirus 
LTRs, such as Moloney leukemia virus, simian sarcoma virus, 
Rauscher leukemia virus, Gibbon-ape leukemia virus, baboon 
endogenous virus and HTLV-I following sequence analysis. No 
significant homology between the BLV-LTR and the LTRs of 
these other retroviruses has been found, however 50% homol­
ogy has been demonstrated in a lOObp segment located in the 
R regions of BLV and HTLV (Burny et al., 1985a; Sagata et 
al„, 1984, 1985b; and Rice et al., 1987b). The LTR is bound 
by TG....CA and a perfect inverted repeat of 6 bases at both 
ends. Other general features include direct repeats (6bp) 
of the host sequence at the provirus integration site, a 
primer (tRNApro) binding site following the 5' LTR, and a 
polyuridine tract (9bp) preceding the 3' LTR (Sagata et al., 
1984; Rice et al., 1987b). The U3 region contains the puta­
tive transcriptional promoters, the "CAT" and "TATA" boxes, 
a polyadenylation signal site, and an enhancer region. The 
enhancer region shows 70% homology with the mouse immuno­
globulin heavy chain gene enhancer, which functions in a B- 
cell-specific manner. U3 is separated from the R region by 
the cap site. The exceptionally long R region (234 bp) 
separates the poly A+ addition signal found in U3 from the 
poly A+ site found at the 3' end of R by 260 bp. The two 
transcription termination sites are brought into close 
approximation when the R region forms a large stable hair 
pin structure on the nascent RNA chain, ensuring normal 
termination. This unique structural feature of the BLV LTR 
R region is also seen in HTLV-I (Sagata et al., 1984). Con­
sensus splice donors for the variously spliced mRNA's (5.1kb 
env and 2.lkb pX) can be found with an 8/9 match in the R 
region of BLV, similar to HTLV-I (Rice et al., 1987b). The 
BLV and HTLV LTRs are type specific promoters, functioning
in only a very restricted set of cells. The BLV LTR, when 
linked to the chloramphenicol acetyltransferase (CAT) gene 
functions only in BLV infected cells, indicating that BLV 
produces a protein to regulate its own promoter activity via 
the LTR (Derse et al., 1985; Derse and Casey 1986; Rosen et 
al., 1985, 1986). Derse (1986, 1987, 1988) used deletion 
analysis to identify two sequences in the viral LTR that in­
fluence gene expression and are acted upon in "trans" by pX 
proteins, p38 and pl8, respectively. These sequences, 5' 
(75bp in U3) and 31 (250bp in R) to the RNA start site, act
as enhancers, functioning in either orientation. However, 
the 250bp sequence must be located downstream of the RNA 
initiation site to function efficiently.
A 97 base untranslated region, following the 5" LTR, acts 
as the primer binding site for tRNApro. This region is short 
when compared to Moloney-Murine Leukemia (M-MuLV) and Rous 
Sarcoma virus (RSV), but longer than the analogous region of 
HTLV-I which is only 26 bases (Rice et al., 1987b).
The Gag Gene
The gag gene is composed of 1179 nucleotides (Rice et al. 
1985). Uckert et al. (1984a) reported the translational 
order of gag, as determined using pactamycin mapping, as 
amino (NH2) terminal plO -(plSj-plS,,) - p24 - pl2 - carboxy 
(COOH) terminal. The presence of plO as a viral structural 
protein is still disputed. Ghysdael et al. (1984), reported 
plO was precipitated by BLV antibody positive sera from in
vitro translation mixtures using 38s RNA and from BLV in­
fected cells. Likewise, Yoshinaka et al. (1986) showed 
cleavage of in vitro synthesized gag-related polyproteins 
produced a myristylated plO, which was composed of the N- 
terminal part of pl5. He also demonstrated its presence in 
intact virus. Rice et al. (1987b) do not mention the pres­
ence of plO as a structural protein of BLV. The (NH2) 
terminal gag protein pl5 is myristylated via the Met-Gly- 
Asn-Ser sequence typical of other retroviruses (Rice et al. 
1987b). It is a basic protein, the major virus phospho- 
protein, and exists in two forms based on gel electrophor­
esis (Burny et al., 1985a; Ghysdael et al., 1984). One 
population of pl5 exists linked to the lipid bilayer of the 
viral membrane, and the other is linked to viral RNA 
(Ghysdael et al., 1984). It is similar to murine pl5 at its 
N-terminal region, but its COOH-terminal end more closely 
resembles avian pl2 (Rice et al., 1987b).
The first recognized and major BLV structural protein is 
p24. It consists of 215 amino acids, and shares the N-ter­
minal proline and COOH-terminal leucine of the p30 of all 
mammalian retroviruses (Ghysdael et al., 1984; Uckert et 
al., 1984b). Significant amino acid homology between BLV- 
p24 and to HTLV-I p24 has been documented. However, BLV-p24 
is only distantly related to any other type C p3 0 proteins 
(Gilden et al., 1975; Oroszlan et al., 1982; Ghysdael et 
al., 1984;). BLV pl2, located at the COOH-terminal end of
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the primary translation product of gag (Ghysdael et al.,
1984) is proline rich (Burny et al., 1985a), and binds 
nucleic acids, a function that is homologous to the HTLV-I 
pl5 (Rice et al., 1987b). There is significant amino acid 
sequence homology between BLV pl2 and HTLV pl5.
Significant, although less, homology with avian and 
mammalian type C viral proteins has also been documented 
(Rice et al., 1987b).
Viral Protease
The viral protease, pl4, is coded from a 585 nucleotide (NT) 
open reading frame (ORF) overlapping the 3' end of gag on 
its 5' end and overlapping the pol gene at its 31 end (Rice 
et al., 1985). However, the protease amino acids do not 
overlap, as 38 codons on the 5' end and 26 codons on the 3' 
end of its mRNA are not included in the final protein pro­
duct (Yoshinaka et al., 1986). Several lines of evidence, 
such as protein mapping of the gag polyprotein precursor, 
the characteristic structure of the mRNA, and promotion of 
the synthesis of a gag polyprotein precursor by lysine tRNA 
in vitro, suggest that the protease could be translated by 
frameshift suppression of the gag termination codon (Yosh­
inaka et al., 1986). BLV protease has sequence homology 
with the viral proteases of the avian and mammalian type C 
virus sequences over its entire length, and is most closely 
related to murine protease demonstrating a 3 0% match in 
nucleotide identities (Yoshinaka et al., 1986; Rice et al.,
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1987b). Most retroviral proteases resemble a single domain 
of an aspartic protease and function in a dimeric form to 
cleave the gag and gag-pol polyprotein into those proteins 
found in the mature virion (Yoshinaka et al., 1986; Pearl 
and Taylor 1987; Rice et al., 1987b).
Reverse Transcriptase and Endonuclease 
The reverse transcriptase is an 852 aa protein, MW 
70,000, (Burny et al., 1980) and is the most conserved of 
the BLV structural genes (Sagata et al., 1985b). From 
residue 5 all the way to the C-terminus of the predicted 
protein, the BLV sequence is highly homologous to that of 
HTLV with 47% identical residues (Rice et al., 1987b). Sig­
nificant homology to murine and avian genomes has also been 
demonstrated (Sagata et al., 1985b). The 3' end overlaps 
the 5' end of the env gene, as in M-MuLV and RSV, and con­
tains the splice acceptor sequence used in the production of 
both the 5.1 mRNA of env and the 2.1 mRNA of the pX proteins 
(Derse 1987; Rice et al., 1987b). Mechanisms of translation 
of the pol gene are not yet known but there are termination 
codons at the end of the gag, protease and RT genes in three 
different reading frames (Rice et al., 1985, 1987b). BLV RT 
function is dependent on RNA and all 4 deoxyribonucleoside 
triphosphates (Ghysdael et al., 1984). Unlike the RT of 
most type C viruses which are dependent on Mn++, BLV RT 




The envelope gene codes for gp51, 268 AA, MW 30,572 and 
gp30, 214 AA, MW 24,082 (Rice et al., 1984). The 5' portion 
of the gene contains the splice donor needed for the produc­
tion of the 2.1 kb mRNA coding for pX proteins (Rice et al., 
1987a). The BLV and HTLV-I large envelope proteins have a 
number of structural similarities (Rice et al., 1987b; Burny 
et al., 1985a). BLV gp51 contains 8 potential glycosylation 
sites, while gp30 contains only two (Sagata et al., 1985b). 
BLV gp30, typical of type C transmembrane proteins, has both 
NH2 and C-terminal hydrophobic areas and of its six cysteine 
residues, four are conserved in all type C viruses. It 
shares 36% homology with HTLV-I p30 env (Rice et al., 1984; 
Schultz et al., 1984).
The Post Envelope Region 
There are 1817 bases between the env gene and 3' LTR of 
BLV, containing three ORFs (Burny et al., 1985a). This area 
has similar genomic structure to both HTLV-I and II and a 
similarity in distribution of hydrophobic and hydrophilic 
regions in HTLV and BLV peptides (Haseltine et al., 1984). 
Two non-structural proteins pl8 and p38, translated from a 
doubly spliced 2.1kb mRNA, from two ORF's have been iden­
tified (Sagata et al., 1985a; Rice et al., 1987a). The key 
sequences used for splicing the 2.1Kb mRNA in BLV are simi­
lar to sequences found in HTLV-I,-II, and STLV (Willems et 
al., 1987). Translation of pl8 initiates from the first AUG
of env and proceeds through the pX SORF, while p38 initiates 
from the second env AUG and proceeds through the pX LORF 
(Rice et al., 1987a). The phosphoprotein, pl8, contains 17 
AA of the env signal peptide and the remainder is coded from 
the pX to produce a 156 AA protein which is high in proline 
and serine content (Rice et al., 1987a). Both p38 and pl8 
act to increase the production of BLV structural proteins, 
acting in "trans" on specific sites of the LTR. P38, with a 
half life of only 6 hours, localizes in the nucleus of BLV 
infected cells (Sagata et al., 1985a). Production of full 
length (9kb) and env (5.1kb) mRNA's requires expression of 
both p38 and pl8 (Derse, 1988). The 75 bp region of the LTR 
acts as a p38-dependent enhancer element, while the pl8 is 
required for the accumulation of the 9 and 5.1 kb messages 
and acts on the stem loop structure found in the long R 
region of BLV (Derse, 1987). P18 may act to stabilize this
structure and result in the accumulation of viral message in 
infected cells (Derse, 1988). Itohara (1988) demonstrated 
trans-activation using LORF or SORF plasmids transfected 
into cells containing the BLV LTR spliced to the env gene.
He found p38 was the major trans-activator, however, pl8 can 
enhance this activity 5 fold.
BLV Production and Cell Culture Systems 
Short Term Cultures 
BLV was first identified by EM visualization of type-C 
particles in PHA stimulated lymphocytes from LS cattle
(Miller et al., 1969). Ferrer et al. (1972) confirmed these 
results using cell cultures from PL cattle and leukemic cow 
serum in immunofluorescence assays. Stock (1972) 
demonstrated that viral budding could take place as early as 
3 hours post culture. All three investigators could detect 
BLV in cultures with or without PHA stimulation and Stock 
deduced in vitro maintenance of cells and not PHA stimula­
tion was responsible for the expression and/or replication 
of the virus.
Gupta and Ferrer (1982) and Gupta et al. (1984) reported 
expression of BLV in short term cultured lymphocytes is 
blocked at the transcriptional level by a non-immunoglobulin 
protein present in the plasma but not in the serum of BLV- 
infected cattle. The effect of this plasma blocking factor 
(PBF) on the production of BLV by lymphocytes in short term 
cultures is reversible. PBF is also found in BLV infected 
sheep, but varies between and within animals depending on 
time of collection (Cornil, 1989). Tsukiyama et al. (1987) 
demonstrated that platelet derived factors (PDF) obtained 
from platelet lysates of both BLV positive or negative 
cattle could inhibit the effect of PBF. This effect, unlike 
that of PBF is irreversible, once added to lymphocytes, PDF 
will induce the continued production of BLV even if PDF is 
subsequently removed and PBF is added. The mechanism of 
action of PDF is not known, however, several factors such as 
platelet-derived growth factor (PDGF) and transforming
growth factor (TGF)-/3, are contained in high titer in plate­
lets. These factors have mitogenic activity, as does PHA, 
and are significantly related to the regulation of cell 
cycles (Tsukiyama et al., 1987). Takashima and Olson (1981) 
demonstrated production of BLV is indeed dependent on cell 
cycle and that the development of BLV in lymphocytes 
requires infected cells to enter the cell cycle from the 
resting stage.
Exogenous factors produced by T-cells can also induce the 
expression of BLV in short term cultures. Paul et al.
(1977) were the first to recognize that although B-cells 
produce BLV, more cells produced virus in mixed cultures of 
PBL than in nylon wool enriched B-cell cultures. They found 
PHA, a T-cell mitogen, increased virus production in puri­
fied B-cell cultures. Similar experiments, with various 
mitogens, were conducted in sheep to further support the 
idea that T-cell factors in some way trigger the transcrip­
tion of BLV in B-cells (Djilali et al., 1987a; Levy et al., 
1987; Cornil et al., 1988). Levy et al. (1987) found that 
BLV expression was not linked to PHA induced B-cell multip­
lication, but as demonstrated by Cornil et al. (1988) did 
correlate with the proportion of T-cells present in the cul­
ture. All three investigators demonstrated conditioned 
media prepared from PHA stimulated normal lymphocytes great­
ly enhances BLV production in short term cultures of puri­
fied B-cells. Djilali et al. (1987a) postulated that PHA
stimulates T-cell factors which act on the BLV enhancer to 
initiate BLV production in a limited number of specific B- 
cell clones, accounting for the in vivo presence of high 
levels of viral antibodies. Chatterjee et al. (1985) demon­
strated that PHA activation of transcription of the BLV 
genome required de novo protein synthesis, however, the 
cells producing this protein were not identified. Perhaps 
inhibition of T-cell triggering is the method of repression 
by the above mentioned PBF. If PBF or some other factor 
found in BLV positive cows does inhibit T-cell triggering in 
vivo, then BLV positive cow sera should inhibit lymphocyte 
function in vitro. Cornil et al. (1988) demonstrated that 
PBF not only blocked production of p24 in both PHA stimu­
lated or unstimulated lymphocytes, but could also decrease 
the normal proliferative response of lymphocytes from either 
BLV infected or uninfected cattle. Takamatsu et al. (1988) 
showed inhibition of the growth of IL-2 dependent bovine T- 
cells and mitogen induced blastogenesis by PHA, Con-A, PWM, 
LPS and protein-A by sera from BLV positive cows.
Long Term Cultures 
Van Der Maaten et al. (1974) developed a persistently 
infected fetal lamb spleen (FLS) cell line by co-culture 
with cells from BLV infected PL and LS cows. The amount of 
virus produced was increased by switching from FLS to fetal 
lamb kidney (FLK) cells (Van Der Maaten and Miller 1975a). 
Graves and Ferrer (1976), using similar co-culture tech-
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niques, developed a persistently infected bat lung cell 
line. The bat and kidney cell lines supply most of the BLV 
used in laboratory research today. However, other cell 
lines have been produced or "BLV transformed" for experimen­
tal purposes (Mamoun et al., 1981; Onuma et al., 1981b; 
Mamoun et al., 1985; Onuma et al., 1986; Burny et al.,
1987b; Slavikova et al., 1987; Altanerova et al., 1989).
Characteristics of BLV Infected Cells 
The majority of circulating lymphocytes from PL cattle 
are primarily B-lymphocytes; however, the proportion of B- 
lymphocytes increases appreciably before any detectable 
increase in the total number of circulating lymphocytes is 
seen (Burny et al., 1987b). The number of B-lymphocytes 
increases from 28% in normal cows to 63% of the total lymph­
ocytes in PL cows (Muscoplat et al., 1974b). These results 
were obtained by a large number of investigators using a 
variety of labeling techniques: Anti-slg, anti-Fc receptor,
anti-thymus serum or PNA and immunofluorescence, spontaneous 
SRBC rosetting, monoclonal or polyclonal B or T-cell anti­
bodies and various lectins (Muscoplat et al., 1974b; Mayr et 
al., 1982; Koyama et al., 1983; Gershwin et al., 1983; Mika- 
lauskine et al., 1984; Esteban et al., 1985; Fossum et al., 
1988; Williams et al., 1988b). Recent studies show that the 
induction of BLV by short term culture may influence the 
regulation and expression of slg and BoLa class II antigens 
(Burny et al., 1987b). Several investigators found cells
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doubly labeled with both T and B-cell markers. Fossum et 
al., (1988), found PL cells reacting with both B and T-cell 
lectins and attributed it to altered sugar compositions 
found on the cell surface. Williams et al. (1988b) and 
Depelchin et al. (1989) both found a population of slg+ B- 
cells in BLV infected cattle that also react with T-cell 
monoclonal antibodies. Depelchin et al. (1989) found this 
population of doubly labeled cells increases in proportion 
to the increased number of total peripheral lymphocytes in 
PL animals.
Although the majority of the PBL in BLV infected cattle 
are B-cells, increases in T-lymphocyte numbers have been 
noted (Dimmock et al., 1986; Burny et al., 1980; Williams et 
al., 1988b). Similarly, T-lymphocytes containing the BLV 
genome have been found and these cells are capable of pro­
ducing BLV antigens during short term lymphocyte cultures 
(Burny et al., 1980; Williams et al., 1988a).
A small percentage of the Ig bearing cells are enlarged, 
seem to be arrested at an early stage of maturation, and 
show an increase in the intensity of fluorescence when 
labeled with anti-sIgM. Burny hypothesized that factors 
that effect the BLV enhancer in "trans" to increase its ex­
pression may also increase slgM via stimulation of the Ig 
enhancer region (Burny et al., 1987b).
The mean lymphocyte response to PHA and PWM, as indicated 
by the degree of 3H-thymidine incorporation was markedly
less for lymphocytes obtained from cows with PL than for 
those obtained from normal cows (Muscoplat et al., 1974a). 
They also observed lymphocytes from PL cows incorporated 
approximately 5 times more tritiated thymidine than did 
lymphocytes from normal cows when cultured without phyto­
mitogens. Similar lectin results were obtained by Djilali 
et al. (1987b) using sheep lymphocytes. Density gradient 
centrifugation techniques were used to separate B-cells from 
a PL cow into a subpopulation that is infected with BLV and 
a noninfected subpopulation that spontaneously incorporates 
3H-thymidine after 3 days in culture (Kenyon and Piper 
1977a, 1977b). The latter population, unlike the malignant 
lymphocytes that are found in the blood of cattle with 
lymphosarcoma, are sensitive to glucocorticoids, both in 
vitro and in vivo. Bloom et al. (1979), after in vivo 
steroid treatment of PL cattle, found an 80-90% decrease in 
the B-cell population, most of which were those that spon­
taneously incorporated 3H-thymidine. The activity of these 
cells can be specifically inhibited in vitro by sera con­
taining BLV antibodies indicating these cells may be respon­
sive to the presence of BLV antigens (Ferrer et al., 1979). 
Jacobs et al. (1981) using a nonstructural antigen isolated 
from tumor cells could cause in-vitro blastogenesis of 
lymphocytes from 69% of LS cattle but only 4% of normal 
cattle.
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Weber et al. (1969) saw an increased frequency in the 
presence of nuclear pockets in lymphocytes of PL and LS 
cows. The presence of these nuclear pockets, seen by EM, 
correlated well with the ability of these cells to produce 
C-type particles when cultured with PHA. However, the per­
cent of BLV infected cells varies from animal to animal and 
within one animal, especially if lymphosarcoma develops 
(Burny et al., 1980).
The diagnosis of tumorigenicity of circulating lympho­
cytes or LS cells depends primarily on morphologic and 
karyotypic findings. Most cases of PL result from a benign 
proliferation of B lymphocytes; however, in LS cases chromo­
somal ploidy is common (Hare et al., 1967). These 
chromosomal changes vary from animal to animal, but also 
within an individual if more than one LN is examined. The 
same cell line is found in each case, suggesting a 
unicentric tumor origin with metastasis (Burny et al.,
1987b).
Onuma et al. (1977) has taken a different approach and 
looked for tumor associated antigens (TAA) on the surface or 
in the cytoplasm of various cells from BLV infected cattle 
and sheep. TAA was expressed in 15/15 LS cattle, 5/5 LS 
sheep, 3/15 AL cattle and 1/7 healthy BLV positive sheep.
In the 3 positive AL cattle, a B-cell population above the 
average for the other 12 cattle was noted. This indicates a 
possible relationship between increased B-cell percentage
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and the appearance of TAA. Onuma et al. (1981a), produced a 
transformed sheep fibroblast cell line by co-culture with 
BLV. The major surface protein expressed on this new cell 
line, SF-28, was a nonstructural protein while that express­
ed on FLK cells was the structural protein gp50. Later in 
1987, at the 107th passage of SF-28 cells, they discovered 
only 0.6% of the cells expressed BLV structural antigens 
while 60-70% expressed a non-structural antigen (Onuma,
1987) . Monoclonal antibodies against TAA identified a 41Kd 
protein using Western blot assays. Circulating anti-TAA 
antibody was found in 8/81 AL, 13/14 PL, and 14/14 LS cattle 
and 4/4 BLV infected but healthy sheep. Two of these sheep 
became negative for p41 antibody one to three months before 
death, however, antibody to gp51 and p24 remained constant. 
Aida et al. (1985a, 1985b) has divided TAA into 3 groups 
based on reactivity with a panel of monoclonal antibodies:
1) common TAA (MW 74kd) found on all tumor cells, 2) par­
tially common TAA found on some tumor cells (MW 64Kd) and 3) 
individually distinct TAA (MW 64Kd). Although Onuma and 
Aida work together, no correlation with the p41 protein 
found by Onuma was mentioned.
BLV Provirus
Kettmann et al. 1978 demonstrated BLV was an exogenous 
oncogenic RNA virus using BLV cDNA as probe. LTR sequences 
flank the provirus which is covalently linked to GC rich 
regions upon integration into the host cell genome (Kettmann
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et al., 1979). In sheep the provirus can be found as unin­
tegrated linear molecules in circulating lymphocytes (Burny 
et al., 1985a). Sites of BLV integration are not rearrang­
ed, are not similar to known oncogenes, nor does BLV seem to 
influence transcription of cellular flanking sequences (Gel- 
mann et al., 1984). Burny et al. (1985a) found minimal 
variation of the provirus among BLV strains derived from 
cattle in different countries using restriction enzyme (RE) 
analysis. Provirus can be found in PBL or lymphoid tissue 
of all BLV infected animals and in solid tumors and tissues 
infiltrated with tumoral lymphoid cells, but not in normal 
organs of LS animals (Kettmann et al., 1978; Ferrer et al., 
1980). Polyclonal proviral DNA integration (at a large 
number of genomic sites) is seen in less than 5% of the PBL 
in AL cattle, but from 25-40% in PL animals. However, in 
tumors, monoclonal integration (at one or very few sites) in 
the majority of cells is found (Kettmann et al., 1979,
1980a, 1980b, 1981). Although bovine tumors are monoclonal 
populations of cells, the integration sites between tumors 
are not conserved. Using hamster X bovine somatic cell 
hybrids and probes made from unique cellular fragments ad­
jacent to single copy proviruses, Gregoire et al. (1984) 
showed BLV integrated in three different chromosomes in 
three separate tumors, demonstrating that leukemogenesis by 
BLV is independent of proviral site of integration. BLV- 
induced tumors can contain proviral genetic information, up
to four copies per ceil, demonstrating the indispensable 
presence of the virus for tumor development. However, 
whether unique or multiple, about 1/4 of the number of pro­
viral copy or copies found may contain deletions (Kettmann 
et al., 1982; Burny et al., 1987b). Tumors with a single 
deleted copy of the genome are known, but it appears that 
all tumors carry the 5 1 LTR and the 3' portion of the pro­
virus (Kettmann et al., 1982; Mamoun et al., 1985; Onuma et 
al., 1986; Ogawa et al., 1987). This implies pX trans- 
activating proteins may be involved in tumor induction.
They could be involved in the trans-activation of host 
factors leading to an irreversible cascade of events that 
results in tumor induction.
Regardless of where the provirus is integrated, BLV is in 
a repressed state, with extremely low or no viral RNA or 
proteins detected in vivo (Ferrer et al., 1980; Portetelle 
et al., 1981; Notzel et al., 1982; Kettmann et al., 1982, 
1985; Burny et al., 1985a). Ferrer et al. (1980) found no 
difference in the number of proviral DNA copies in PBL of AL 
versus PL cattle when they compared them before and after in 
vitro culture. However, they did find significant amounts 
of RNA present after in vitro culture, demonstrating the 
genome must be repressed at the transcriptional level in 
vivo. Burny et al. (1987b) grew four bovine and two ovine 
tumors in vitro and found only 2 expressed viral antigen 
while four had no detectable viral RNA or viral proteins.
Probes from the conserved 3' pX region also do not detect 
significant viral message in some cultured tumor cells 
(Kettmann et al., 1985). Altanier et al. (1987) found non­
producer FLK-BLV cell lines which do contain a full length 
proviral copy. Assuming these tumors were all induced by 
BLV, it seems the virus is necessary as an inducer of the 
neoplastic process but is dispensable once the process is 
switched on. Burny et al. (1985b) hypothesized that after 
transformation of the infected cell, extinction of provirus 
expression is a mandatory step allowing the neoplastic cell 
to escape immune surveillance while proliferating. However, 
continual production of antibody, in the absence of further 
exposure to virus, indicates that some mechanism for antigen 
expression must be operational, because antibodies do not 
persist in cattle immunized with killed virus (Miller and 
Van der Maaten, 1980).
Detection of BLV Infection 
The earliest diagnostic test for BLV was based on the 
presence of increased lymphocyte counts and various leukosis 
keys were proposed and used (Straub 1987a). Many BLV diag­
nostic tests have been used, some of the earliest were 
complement-fixation (CF) (Miller et al., 1974), rapid syn­
cytia induction (SIA) (Diglio and Ferrer 1976, Ferrer and 
Diglio 1976), radioimmunoprecipitation (RIP) (Devare et al., 
1977; Schmerr and Goodwin 1981a), virus neutralization (VN) 
(Ferrer et al., 1977) and agar gel immunodiffusion (AGID)
using p24 as antigen (Miller et al., 1974). Straub et al.
(1978) compared the use of either p24 or gp50 as antigens in 
AGID assays. The majority of cows tested produced antibody 
to both p24 and gp50, however, a small number produced 
detectable antibody to only gp50. By 1980, the AGID test 
had been standardized using both gp50 and p24 (Committee on 
Bovine Leukemia Virus, 1980). Because of its increased sen­
sitivity and ease of use, the AGID soon became one of the 
most popular diagnostic assays (Burny et al., 1980). The 
enzyme-linked immunosorbent assay (ELISA), using cell super- 
nates containing BLV or purified gp as antigen showed 
similar results to those obtained for the gp50 - p24 AGID; 
however, quantitative results could be obtained with the 
ELISA system (Todd et al., 1980, 1982? Poli et al., 1981; 
Graves et al., 1982). Several labs compared the various BLV 
detection methods (Devare et al., 1977; Ferrer et al., 1977; 
Kaaden et al., 1978; Bex et al., 1979; Mammerickx et al., 
1980; Miller et al., 1981; Poli et al., 1981; Graves et al., 
1982; and Djilali et al., 1987b). All sampling techniques 
were not used by each investigator, nor did all 
investigators obtain consistent comparisons. However, for 
the positive detection of BLV antibodies in the sera of BLV 
infected cattle most indicated RIA using gp51 > RIA using 
p24 > VN = SIA > AGID = ELISA > Fab = EM. There was a 96% 
or greater agreement between all testing methods used except 
Fab and EM, which were used only in the very earliest tests.
Most discrepancies appeared when the antibody titer was very 
low. One of the most sensitive and easiest ways to screen 
large numbers of both serum or milk samples and be as ac­
curate as RIA without the use of radiolabelled materials is 
the anti-gp50 monoclonal ELISA. The anti-gp50 antibody, 
attached to the ELISA plate, binds to BLV obtained from a 
crude prep of clarified supernates from BLV infected cells. 
This method is more sensitive than the more widely used AGID 
to screen large numbers of sera (Portetelle et al., 1983, 
1987, 1989c; Mammerickx et al., 1984; Florent et al., 1988). 
Western blots using whole virus as antigen were used by 
Deshayes et al. (1977), Walker et al. (1987) and Heeny et 
al. (1988) to detect BLV antibodies.
BLV Serum Antibodies 
BLV infected cattle have been found to possess antibodies 
to at least six structural (gp50, gp35, p24, pl2, pl5, RT) 
and two nonstructural proteins (pl8, p38). However, the 
presence of antibodies to the various proteins is dependent 
on the stage of disease progression (Heeny et al., 1988; Wu 
et al., 1977; Deshayes et al., 1977, 1980; Portetelle et 
al., 1981; Willems et al., 1987, 1988). Viremia can be 
monitored only the first 10-12 days post infection, preced­
ing the appearance of virus neutralizing antibody (Burny et 
al., 1987b). Anti-gp50 antibodies appear 2-4 weeks post in­
oculation in both sheep and cattle, followed closely by the 
appearance of p24 antibodies (Miller and Van Der Maaten
1975; Portetelle et al., 1981; Cockerell et al., 1986; and 
Djilali et al., 1987b). Most surveys demonstrate a steady 
rise in antibody titers with disease progression in both 
sheep and cattle (Ferrer et al., 1974, Bex et al., 1979; 
Mammerickx et al., 1980; Kono et al., 1981; McGuire et al., 
1981; Portetelle et al., 1978, 1981; Thurmond et al., 1985; 
Heeny et al., 1988). However, there are large individual 
variations, especially in sheep, and antibodies to BLV do 
not seem to influence disease progression or fatal onset of 
the tumor phase. Variations in antibody titer that were 
significant enough to alter the classification of animals 
from positive to negative or negative to positive were seen 
in 36/254 cattle tested over a four year interval (Kaaden et 
al., 1978). This may be explained in part by the finding of 
Burridge et al. (1982), who reported a significant fall in 
antibody titer occurred in cattle at the time of calving 
with a subsequent rise within one month. They theorized the 
titer decrease was due to passage of circulating antibodies 
into the colostrum. Bex et al. (1979) found p24 and gp51 
antibodies present in milk, although at much lower levels 
than in serum.
Although the presence of circulating antibodies remains 
high, the significance of antibodies against individual 
proteins has not yet been determined. Kono et al. (1981), 
McGuire et al. (1981) and Thurmond et al. (1985) observed 
higher titers to p24 in LS cattle than in "clinically"
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normal BLV positive animals, suggesting a relationship 
between increased p24 antibody and malignancy. Similarly, 
Heeny et al. (1988) found sero-positive cattle with lymphoma 
reacted to more BLV antigens than infected healthy cattle as 
determined by Western blot analysis. All sero-positive 
cattle reacted with p24 and gp50; clinically normal sero­
positive cattle reacted only occasionally with plO and pl2, 
and less than half the time with gp35; while LS cattle had 
high titers to plO and pl2, and most reacted with variable 
intensity to gp35. In an earlier study, Deshayes et al. 
(1980) using RIP, reported similar results, however, she 
attributed these findings to quantitative differences in 
antibody titers found between non-LS and LS cattle. Heeny 
et al. (1988), however, saw no consistent relationship bet­
ween cases with higher antibody titers and the number of BLV 
antigens identified using ELISA and Western assays.
Antibodies directed against BLV are usually of the IgG1 
and IgA subclasses (Burny et al., 1980; Heeny et al., 1988). 
Infection of cattle with BLV appears to affect the synthesis 
or release of IgM as evidenced by lower than normal levels 
found in serum of PL and LS animals. The IgG levels seem to 
remain constant (Trainin et al., 1981; Meiron et al., 1985; 
Heeny et al., 1988). In sheep, an absence of any non­
specific immunosuppressive effect of BLV was demonstrated by 
analysis of serum IgG concentrations, immunization with 
rabbit RBC and skin testing (Cockerell et al., 1986). In PL
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cattle and LS sheep, BLV does have the specific immunosup­
pressant effect of decreasing natural cellular cytotoxicity 
of lymphocytes against FLK-BLV cells (Yamamoto et al., 1984,
1985).
Portetelle et al. (1978) demonstrated an increase in 
complement dependent antibody cytoxicity (CDAC) which paral­
leled an increase in anti-BLV titer in sheep, even after the 
onset of the LS stage. Contrary to this, two later studies 
demonstrated CDAC against FLK-BLV cells did not increase 
with time (Honma et al., 1980; Schmeer et al., 1981b). CDAC 
is directed against gp50, the important antigenic epitopes 
of which are carbohydrate (CHO) moieties (Portetelle et al., 
1981; Schmeer et al., 1981b). Tunicamycin treatment of FLK- 
BLV target cells, reduced the CDAC response found using BLV 
positive cow sera by 80% to 30%.
BLV gp50 was characterized using a panel of 15 monoclonal 
antibodies developed by Bruck et al. (1982a, 1982b, 1984). 
Out of eight antigenic sites recognized, four were conforma- 
tionally dependent (C, F, G, H) and three (F, G, H,) were 
biologically significant. The latter mediated infectivity, 
syncytia induction and acted as the targets of CDAC activity 
found in sero-positive cows (Burny et al., 1985b; Portetelle 
et al., 1989c). Reactivity against these CDAC epitopes is 
dependent upon both conformation and glycosylation. Epi­
topes F, G, and H are absent from tunicamycin treated FLK- 
BLV cells which produce unglycosylated gp50 (Schmerr et al.,
1981b), and treatment of gp50 with SDS and 100"C heat will 
totally destroy their reactivity with cattle serum (Burny et 
al., 1985b). Portetelle et al. (1989a, 1989b, 1989c), 
located epitopes F, G, and H at the N-terminal region of 
gp51, from AA 35 to 95. Surprisingly, variations in the 
three epitopes are not rare and viral mutants lacking one or 
two of these epitopes are known. However, no variant lack­
ing all three epitopes has been found.
Most recently, antibodies to the pX nonstructural pro­
teins have been demonstrated in various BLV infected cow 
sera. Willems et al. (1987, 1988) and Burny et al. (1987a) 
expressed cDNA clones corresponding to the LORF of BLV in 
various expression systems to produce the "trans" acting 
protein p34 (p38). Reactivity to p34 (p38) was found using 
sera from cattle in the LS stage and practically all sera 
from BLV infected sheep. Yoshinaka et al. (1985) expressed 
a 14kd protein corresponding to the SORF of BLV and found it 
reacted with 2/11 LS cow sera tested. As previously stated, 
the 3' end of the BLV genome encodes the pX proteins and is 
conserved in all tumors analyzed to date. The induction 
and/or maintenance of the tumor stage by the expression of 
px would account for an increased proportion of px positive 
sera during this LS stage. Expression of pX proteins may be 
kept at a minimum by host regulatory factors during early 
stages of the disease, but due to unknown causes be dere­
pressed thus inducing the tumor phase. Burny et al. (1985a)
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discusses the presence within a 150bp region of pX of 4 
identically spaced oligomers in both BLV and HTLV-I. The 
lack of third base changes in these oligomers, which would 
be expected in bases encoding conserved amino acids, tends 
to suggest these sites may function in a regulatory manner. 
Perhaps regulation via these sites limits the expression of 
p38 and pl8 during earlier stages of disease.
Vaccination
Lambs harboring maternal passive antibodies are fully 
protected against challenges with massive amounts of BLV 
infected cells. However, as passive antibody titers dropped 
to low values, animals became fully sensitive to the chal­
lenging infectious material (Burny et al., 1985c). It seems 
safe to assume, then, that vaccination using the appropriate 
antigen or antigenic epitopes might well be protective. 
Recent vaccine production has centered around the use of 
gp50 antigenic epitopes in a form recognized by the animal. 
These vaccines include the use of gp50 ISCOMS (Merza et al., 
1989); a recombinant Vaccinia virus containing the gene for 
gp50 (Ohishi et al., 1988) and KLH conjugated synthetic 
peptides of the N-terminal portion of gp50 (Portetelle et 
al., 1989b). Further research may well find the answer to 
prevention of both BLV and its closely related relatives 
HTLV I and II, and STLV.
There is a lack of information on the correlation of the 
humoral immune response of BLV infected cattle, with BLV
induced clinical findings. While increased reactivity to 
many BLV proteins seems to be found in advanced stages of 
the disease, random surveys cannot be used to correlate this 
antibody response data to the time of transition from one 
state (such as AL) to a second state (such as PL). Also, 
most studies have reported anti-p24 or gp50 antibody produc­
tion and have not followed the production of antibody to all 
structural and non-structural BLV proteins. The importance 
of the presence of anti-pX antibodies to the progression of 
EBL is unknown at present. However, the idea that these 
proteins can be expressed on the cell surface and thus can 
become a target for both humoral or cell mediated immune 
responses is supported by their presence. Further inves­
tigation into both of these areas needs to be conducted.
This study was designed to address these questions by 
obtaining sequential serum samples from BLV positive cattle 
following a planned infection. The developing immunological 
response of BLV infected cattle to various BLV proteins can 
then be correlated with disease progression based on the 
progressive accumulation of clinical data.
Chapter II
Evaluation of Western Immunoassay for Detection 
of Bovine Leukemia Virus Proteins.
Introduction
Bovine Leukemia Virus (BLV), a type C exogenous 
retrovirus is the etiologic agent of Enzootic Bovine 
Leukosis. It can induce a benign lymphoproliferative 
disease in infected cattle, which, with time, may progress 
to a lymphosarcomatous stage (Miller and Van der Maaten 
1980). Animals develop a humoral immune response within 
weeks following BLV infection. The major response is 
against the envelope protein gp50 and the core protein p24, 
however, antibody against other viral structural proteins 
(gp30, pl5, pl2, plO) and the nonstructural proteins (pl8 
and p38) has been reported (Deshayes et al., 1977, 1980; 
Portetelle et al., 1978; Mamoun et al., 1983a; Sagata et 
al., 1985a; Yoshinaka et al., 1985; Heeny et al., 1988).
Many studies have attempted to characterize the humoral 
immune response of BLV infected cattle (Ferrer et al., 1974; 
Bex et al., 1979; Mamerickx et al., 1980; Kono et al., 1981; 
McGuire et al., 1981; Portetelle et al., 1981). The agar 
gel immunodiffusion (AGID) test is the most widely used test 
to diagnose BLV (Burny et al., 1980). The AGID detects 
antibody to gp50 and is simple to use, but has limited 
sensitivity. A radioimmunoassay (RIA) detects antibody to 
gp50 or p24, is very sensitive, but requires radiolabelled
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antigen (Mammerickx et al., 1980). An enzyme linked 
immunosorbent assay (ELISA) uses partially purified BLV as 
antigen, but high background staining associated with bovine 
sera interferes with interpretation of the results in many 
cases (Todd et al., 1980, 1982; Portetelle et al, 1983,
1987). A more sensitive gp50 antigen capture ELISA is 
available, but this requires monoclonal antibodies against 
epitopes of gp50 that do not interfere with the binding of 
bovine antibodies (Mammerickx et al., 1984; Portetelle et 
al., 1989c). Western blotting procedures have also been 
published, but do not always adequately detect the presence 
of viral proteins especially the envelope glycoproteins 
(Walker et al., 1987; Heeny et al., 1988). We have 
developed a simplified Western immunoassay to detect anti- 
bovine immunoglobulin to all the BLV structural proteins.
We used this system to follow the development of the humoral 
immune response of 12 cattle experimentally infected with 
BLV and compare this detection method with AGID and ELISA 
assays.
Materials and Methods 
Serum Samples and Monoclonal Antibodies
Serial serum samples were taken from 12 cattle over a 
two year period following experimental infection with BLV. 
Twenty-five samples per cow were obtained for a total of 300 
samples. Inoculation and characterization of these cattle 
(6 AL and 6 PL) has been described (chapter 3). Monoclonal
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antibodies for use as controls in the detection of gp50 and 
p24 have been characterized elsewhere (Chapter 4).
Antigen Preparation 
Antigen was prepared from pelleted supernate of BLV 
infected or uninfected FLK cells (Van der Maaten and Miller 
1975a; Freshney, 1983; Chapter 3).
Agar Gel Immunodifffusion 
All serum samples were tested for precipitating 
antibodies to commercially prepared BLV glycoproteins using 
the standard AGID test (Leukassay-B, Pittman-Moore Inc., 
Washington Crossing, NJ). This antigen preparation contains 
BLV-gp50 and a small amount of p24. Antibody reactivity was 
classified as very weak, weak or positive depending on the 
positions of the precipitation line.
ELISA Assays
ELISA assays using partially purified (pelletted) BLV 
as antigen were preformed as described (Todd et al., 1980, 
1982; Chapter 3). Serum samples were tested at dilutions of 
1:50, 1:100 and 1:200.
Western Blots and Immunodetection 
Proteins of pelletted BLV were separated on 12% non­
denaturing gels using a modification of the technique 
described by Hames and Rickwood (1981). Neither the 
stacking nor separating gels contained SDS. Samples 
(800ug/gel), after dilution in sample buffer (0.05M Tris-HCl 
pH 6.8, + 10% glycerol + Bromophenol blue + 0.1% SDS), were
applied to each gel and electrophoresed at 4 watts for ap­
proximately 4 hours. At the completion of the run, the gels 
were transferred to nitrocellulose paper in ethanolamine 
transfer buffer [4.6ml ethanolamine (Sigma, St. Louis, MO) + 
5.6g glycine (Bio Rad laboratories, Richmond, CA) + 500ml 
MeOH + 2500ml dH20] with a Bio Rad Trans-Blot apparatus (Bio 
Rad Laboratories, Richmond, CA) at 75 volts for 2 hrs (Tow- 
bin et al., 1979). To ensure proper transfer of proteins, 
gels were stained with Coomassie Brilliant Blue [0.2% 
Coomassie Brilliant Blue 250 (Bio Rad laboratories, Rich­
mond, CA) dissolved in 50% methanol-dHzO plus 7% glacial 
acetic acid] and the nitrocellulose paper was stained with 
Ponceau S [0.5% Ponceau S (Sigma, St. Louis, MO.) in 1.0% 
acetic acid]. Nitrocellulose paper was dried in a vacuum 
oven overnight (34°C) and cut into strips.
The nitrocellulose membrane strips were rinsed on a 
rocking platform in 150 mM NaCl, lOmM Tris-HCL pH 7.4, (TBS) 
for 5 minutes, blocked for 1 hr in a skim milk solution 
(similar to BLOTTO [Johnson et al., 1984], marketed by Bio 
Rad Laboratories, Richmond, CA with their HIV immunoblot 
detection kit #1971009, a gift from Dr. Ruth Kibler) and 
incubated overnight with bovine serum diluted 1:200 in the 
same blocking solution. Serum was removed by three five 
minute washes, two with 1M NaCL + 0.05% Tween followed by 
one with 1M NaCL. Peroxidase conjugated goat anti-bovine 
IgG (H&L) (Pel-Freez, Rogers, AK) 1:1000 in TBS was then
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added and incubated for 2 hrs. After washing, samples were 
reacted with substrate (0.5mg/ml 4-chloro-l-naphthal + 5ml 
methanol + 25ml 0.05M Tris pH 6.8 + 12ul 30% H202) . The 
reaction was stopped ater 20 min. by rinsing with distilled 
water. This process produced easily interpretable blots for 
our BLV system.
All 24 serum samples (weeks 0 and 2-103) from one cow 
were tested at the same time on nitrocellulose strips trans­
ferred from one gel and all assays for each of the 12 
experimental animals were conducted using the same reagents 
and stock solutions. To confirm relative locations of the 
two major BLV proteins gp50 and p24 on each of the 12 sets 
of nitrocellulose strips, a control strip was run using a 
mixture of monoclonal antibodies against gp50 and p24 as 
described (chapter 4). Strips were also reacted with Con-A 
to confirm the glycoprotein nature of certain proteins 
(Clegg, 1982).
Strips were analyzed on a Chromoscan 3 Densitometer 
(Joyce Loebel, England) and evaluated using the associated 
Joyce Loebel computer assisted analysis program. Linear 
scans were plotted, valley to valley background corrected, 
and peaks spotted to produce a corrected linear scan.
Figure 1 shows a corrected linear scan for week 12 PI of cow 
149, who recognized all the BLV structural proteins. Due to 
the overlap of peaks resulting from reactivity to both a 
wide band at gp50 and a 70kd protein, integral values
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Figure 1. After isonunoblotting, nitrocellulose 6trips were 
read using a Joyce Loebel Chromoscan 3 Densitometer. Linear scans were plotted, valley to valley background corrected, 
and peaks spotted to produce a corrected linear scan. BLV proteins identified are labeled.
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representing the total area under a curve could not be 
calculated. Maximum peak heights were therefore used to 
evaluate antibody responses.
Results
Of the three diagnostic tests used, serum antibody res­
ponses to BLV were detected earliest by the Western 
procedure, followed by ELISA and finally AGID. In several 
instances, a positive test, indicating production of 
antibody against BLV, was followed by a negative test using 
AGID and ELISA, but not using the Western immunoassay (Table 
1) •
AGID results (Table 2), recorded as very weak positive 
(+), weak positive (++) or positive (+++), indicated sero­
conversion occurred at 3 weeks post infection in 3 cows, 4 
weeks PI in 3 cows, 5 weeks PI in 2 cows and one cow sero- 
converted during each of weeks 7, 8, 9 and 11. In six of 
these cows, 86, 93, 94, 123, 131 and 132, identification of 
antibody to BLV was followed by a negative tast. Four of 
these, 86, 93, 94 and 123 were negative for only one week, 
while two cows, 131 and 132 were each negative for 5 
tests/weeks after having been positive at weeks 4 and 5 PI. 
In all but cow 86, these reversions occurred during the 
first 10 weeks PI. Although cow 86 had a strong positive 
response by week 5 PI her antibody response became progres­
sively weaker, was negative by week 59, but a very weak 
positive thereafter.
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Table 1. Comparison of sero-conversion times detected 
by AGID, ELISA and Western blot analysis.
Cow # AGID ELISA
Western
Blot
76 51 4 3
86 5 3 2
93 4 2 2
94 3 3 2
99 11 3 2
122 3 3 2
123 8* 3 2
131 4* 3* 2
132 4* 3 2
140 7 3 2
144 9 3 2
149 3 3 2
1Weeks post infection.
*These samples were positive but subsequent samples were 
negative for a period of time before again becoming posi­
tive. See appendix or text for individual results.
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Table 2. Results of Agar Gel Immunodiffusion Test
Wk
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10 + wk vwk vwk
11 + wk vwk vwk wk
12 + wk vwk vwk wk
16 + wk + wk +
20 + vwk + vwk +
25 + vwk + vwk +
34 + vwk + wk +
43 + vwk + wk +
51 + vwk + wk +
59 + + wk +
68 + vwk + wk +
77 + vwk + wk +
85 + vwk + wk +
94 + vwk + wk +
103 + wk + wk +
Cow numbers
122 123 131 132 140 144 149
wk +
wk vwk vwk wk
wk vwk vwk wk
wk +
wk wk +
+ vwk + +
+ + vwk wk
+ vwk + vwk wk
+ wk vwk vwk + vwk wk
+ + vwk vwk + vwk wk
+ + + wk + + wk
+ + + + . + + wk
+ + wk + + vwk wk
+ wk + + + + wk
+ + + wk + wk wk
+ + + wk + wk wk
+ + wk wk + + wk
+ + wk + + + +
+ + + + + + +
+ + + wk + + wk
+ + + + + + +
+ + + + + + +
ELISA results were more sensitive and more likely to 
identify an antibody positive cow. In general, cows were 
grouped as high, intermediate or low responders based on 
their reactivities to BLV at a 1:100 serum dilution over the 
103 week experimental period (Figure 2, panels A, C and E). 
Although the majority of the cows produced increasing 
amounts of antibodies over time using ELISA assays, there 
was no relationship between BLV antibody reactivity 
demonstrated by ELISA and intensity of response or number of 
proteins identified on Western immunoblots (Table 3).
Antibody responses measured by Western blot procedures 
demonstrated a wide range of reactivities to the different 
BLV proteins, but unlike the ELISA or AGID results, no low 
or borderline responses were obtained that would lead one to 
mis-diagnose the BLV infected status of the 12 experimental 
animals. The Western immunoblot demonstrated reactivity 
with bovine serum to five structural proteins, gp50, gp30, 
p24, pl5, pl2 and plO; two proteins of 70 and 45kd and 
glycoprotein dimers of 162 and 85kd. Evolution of antibody 
titers to the viral proteins varied widely between and 
within animals over time. Some animals had similar antibody 
responses to all the major viral proteins (Cow 99, Figure 
3), while others had directly opposing responses even to 
proteins which are produced from the same polyprotein 
precursors (Cow 94 gp50 & gp30, Figure 4). Antibody rose 
slowly in some (Cow 93, Figure 5) and quickly in others (Cow
Reactivity of Serum on ELISA versus 
Reactivity to gp50 using Western Immunoassay.
Figure 2. Elisa data is shown in panels A, C and E. 
Western data of reactivity to gp50 is shown in panels B, 
and F. Cows are grouped into high (A & B), intermediate 
& D), and Low (E & F) responders based on their ELISA 
results. Each group (A & B, C & D, E & F) contains four 
cows, 2 AL and 2 PL.
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Table 3. Reactivity to BLV Proteins as detected by
Western Immunoassay
ENV GAG
Cow # gp50 gpso p24 pl5 pl2 plO
Low1
94-AL 22 22 17 16 14 -
149-AL 22 20 23 15 15 15
131-PL 20 22 23 5 5 14
132-PL 20 23 22 13 13 7
Inter
86-AL 20 22 23 12 7 -
144-AL 18 22 23 1 9 -
122-PL 21 22 23 1 11 -
140-PL 20 22 23 12 16 9
High
76-AL 19 19 23 - 14 1
99-AL 22 22 23 1 8 -
93-PL 23 23 23 - 13 -
123-PL 20 22 23 5 8 4
'Low, Inter and High are the Low, Intermediate and High
groups assigned according to results of the ELISA assay •
Each group of four cows has 2 AL and 2 PL animals.
2The total number of times this protein was observed on 
Western blots over the 103 week experimental period. A 
total of 24 serum samples were run for each animal.
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Figure 3. Western Immunoassay was run as described in text. The major BLV proteins 
are labeled. Cow 99 had similar antibody reactivity to all three major viral 
structural proteins, p24, gp30 and gp50.
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Figure 4. Western Immunoassay was run as described in text. The major BLV proteins 
are labeled. Cow 94 had an increased response to gp30 early PI, but lost this 
reactivity later. In contrast, reactivity to gp50 was low early PI but increased 
late PI.
















Figure 5. Western Immunoassay was run as described in text. The major BLV proteins 
are labeled. Cow 93 took several weeks to develop a strong antibody response to the 
BLV structural proteins.
86, Figure 6). Once elevated, the antibody response to a
particular protein remained stable in some animals (cow 140
gp50, Figure 7), regressed slightly (Cow 140 gp30, Figure 7) 
or disappeared completely (Cow 86 gp30, Figure 6). In the 
majority of the animals, response to gp50 increased over 
time, but response to gp30 and p24 was more variable
(Figures 3-7, Cows 86, 93, 94, 99, 140). Reactivity to p24
showed an early peak PI in most cattle in the AL stage of 
disease progression, but in PL animals p24 generally 
increased after conversion to the PL stage. Antibody to the 
smaller gag proteins, pl5, pl2 and plO was observed in the 
majority of the cows, however, this reactivity was observed 
primarily during the first 12-16 weeks PI and tended to 
diminish thereafter (Table 4).
Reactivity of glycoproteins with Con-A was apparent 
with gpl62, gp85 and gp50. Although gp30 produced a wide 
band on Western immunoassay as did the other glycoproteins, 
it failed to react with Con-A (Data not shown).
Discussion
The accurate diagnosis of animals with low level antibody 
response to BLV has been a problem in many serologic 
studies. Various assays have been used to increase the 
sensitivity of antibody detection over the standard AGID 
test, but these require the use of specialized reagents 
including radiolabelled antigen for RIA (Deshayes et al., 
1977) or a source of specific anti-gp50 monoclonal
Western Immunoblot of Cow 86
COW 86
200
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Weeks post infection
Figure 6. Western Immunoassay was run as described in text. The major BLV proteins 
are labeled. Cow 86 developed a strong antibody response to the BLV structural 
proteins very quickly, but this response decreased after about 5 months, with 
reactivity to gp30 disappearing completely.
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Weeks post infection
Figure 7. Western Immunoassay was run as described in text. The major BLV proteins 
are labeled. Cow 140 had a strong response to gp50 which remained high throughout 
the experimental period. However, the response to gp30 and p24 decreased with time 
PI.
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Table 4. Antibody Reactivity to the Small Gag Proteins
1 pl5 pl2 plO
I 9 II III I II III I II III
(12) (6) (6) (12) (6) (6) (12) (6) (6)
AL
76 — — — 103 4 — — — —
86 10 2 - 7 - - - - -
94 8 6 2 11 2 1 - - -
99 - 1 - 5 3 - - - -
144 1 - - 7 2 - - - -
149 6 4 5 9 6 — 9 5 1
PL
93 — — — 10 2 1 — — —
122 1 - - 8 1 2 - - -
123 3 1 1 7 1 - 4 - -
131 3 2 - 3 2 - 9 4 1
132 8 5 - 8 5 - 5 2 -
140 10 2 10 5 1 9
1I, II and III represent time periods post infection. I = 
weeks 1-12, II = weeks 16-51 and III = weeks 59-103.
2Total number of samples run during the time periods 
indicated.
3The total number of positive samples showing reactivity 
with a particular protein during the time period given.
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antibodies for the gp50 antigen capture ELISA (Portetelle et 
al., 1983; Mammerickx et al., 1984). Both assays must also 
contend with a high level of non-specific background binding 
commonly found when dealing with bovine serum. We have 
developed a Western immunoassay which can resolve all of the 
BLV structural proteins including the 50 and 30Kd envelope 
glycoproteins. This assay was used to follow the serum 
antibody response over time of cattle experimentally 
infected with BLV and was compared to antibody detection by 
AGID and ELISA assays.
A non-denaturing Western system was choosen to preserve 
the important conformational epitopes of gp50. The immune 
response of BLV infected cattle to gp50 is primarily 
directed against the CHO and conformationally dependent F, G 
and H epitopes which are destroyed by SDS and heating (Burny 
et al., 1985b). Our nondenaturing system allowed us to 
detect bovine antisera binding to wide bands of both gp50 
and gp30 as well as two larger viral glycoprotein dimers of 
162 and 85kd in the majority of samples tested. The latter 
two proteins are probably due to the non-denaturing system 
used resulting in single (85kd) or double (162kd) gp50/gp30 
dimers as reported by Mussgay et al. (1980). The 
glycoprotein nature of the larger molecular weight proteins 
was confirmed by reactivity with Con A, though gp30 was not 
detected. Similar results have been reported by Deshayes et 
al. (1977), using the periodic acid-Schiff stain and is
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probably due to the low carbohydrate content of gp30.
Non-specific background staining was eliminated in most 
cows by the careful screening of all reagents used. Both 
serum and peroxidase conjugated second antibody were tested 
at various dilutions to determine that combination which 
allowed the detection of all BLV proteins with the minimum 
of background from both high and low antibody responders (as 
determined previously by ELISA reactivity to whole BLV). 
Serial dilutions of serum from 1:80 to 1:1,280 and 
peroxidase conjugated second antibody of 1:500 to 1:4000 
were tested. Alkaline Phosphatase conjugated second 
antibody (Blake et al., 1984), was also tested as an 
alternative to peroxidase but was found to increase 
background non-specific binding without a proportionate 
increase in specific reactivities for this system.
Background was also controlled by use of a blocking 
agent both before and during antibody application. Of all 
blocking agents tested, the BLOTTO-like skim milk solution 
from Bio Rad proved most effective. The one factor that 
contributed most toward the reduction of background non­
specific binding was the three 5 minute 1M NaCl washes. The 
improvement over washes using PBS was dramatic. After final 
reagent specifications were established, the clarity of 
antibody reactivity with the various protein bands was 
further increased by decreasing the amount of antigen run on 
each gel.
As a result of these modifications, the Western 
immunoblot assay was the most sensitive serodiagnostic test 
used in this study. Antibodies against p24 were detectable 
in all but one animal by 2 weeks PI and this animal reacted 
by 3 weeks PI. ELISA reactivity followed closely with a 
positive test in all cattle by 4 weeks PI. The AGID test 
did detect seroconversion by 3 weeks PI in three cattle; 
however, up to 11 weeks were needed to detect an adequate 
antibody response in all cattle. In both the ELISA and the 
AGID test, the primary antigen is gp50, although small 
amounts of p24 is present in the AGID and reactivity with 
p24 is possible on the ELISA as evidenced by reactivity with 
anti-p24 monoclonal antibodies (chapter 3). Antibodies 
against gp50 are usually the first to appear following BLV 
infection followed closely by the appearance of anti-p24 
antibodies (Miller and Van der Maaten 1975; Portetelle et 
al., 1981; Cockerell et al., 1986; Djilali et al., 1987b) 
however the detection of p24 before gp50 using RIA has also 
been reported (Miller et al., 1981).
If one follows only the antibody reactivity to gp50 on 
Westerns, the sensitivities of the assays change. The ELISA 
is most sensitive and AGID detected seroconversion one week 
earlier or at the same time as the Western in 67% of the 
animals tested. The reason for the difference in gp50 
reactivity could be explained by dilution factors or changes 
in pertinent conformational epitopes of gp50. Since F, G
and H are the primary epitopes of gp50 against which most 
cattle develop an immune response and expression of these 
epitopes is both carbohydrate and conformationally dependent 
(Bruck et al., 1982b; 1984; Portetelle et al., 1989b), it 
would follow that those assays which would denature gp50 the 
least would be the most sensitive in detecting anti-gp50 
antibodies. In both the ELISA and AGID the primary antigen, 
gp50, would be less denatured than in the native Western 
procedure. Although AGID is generally considered less 
sensitive than other test procedures, its agreement with 
Western gp50 results in this case may also be due to 
differences in serum dilutions used in the various assays. 
The AGID used undiluted serum, while both the ELISA and 
Western used diluted serum.
The major advantage of the Western over the other two 
diagnostic tests concerns the detection of cattle with low 
level antibody responses. False negative tests, resulting 
from low antibody titers (Poli et al., 1981; Miller et al., 
1981; Todd et al., 1982) have been attributed to recent BLV 
infections, the cow being close to parturition (Burridge et 
al., 1982), or naturally occuring, consistently low antibody 
titers (Kaaden et al., 1978). In this study Western 
immunoblots were consistently able to identify those animals 
infected with BLV earlier post infection than either the 
AGID or the ELISA assays. Furthermore, no animals were 
subsequently found negative using the Western after initial
seroconversion, as were one ELISA and 6 AGID tests. The 
apparent sensitivity and specificity of the Western 
immunoassay lies in the ability to detect all viral 
proteins. Although high backgrounds did occur in a few 
samples on the Western, an easily recognizable pattern of 
BLV reactivity was readily identifiable above background.
In a cow with low antibody titers to gp50, reactivity to 
other viral proteins on the Western can establish a positive 
BLV response in this animal. Cow 86, for example, was 
negative by AGID week 59 PI but was positive to gp50, gp30, 
p24 and pl2 on the Western immunoblot at this time.
Likewise, four cattle, with very low level reactivity to 
whole virus on ELISA, two of which might have been 
considered negative on ELISA if background values had been 
much higher, showed a distinct pattern of reactivity to the 
individual proteins on Western immunoassay leaving no 
question of their BLV antibody status.
The difference between the responses demonstrated by 
Western blot and the rather weak reactions shown by ELISA 
for some cattle may have been due to the reagents used to 
dilute the serum samples. The ELISA diluent contained 0.1% 
Triton X-100 while the serum diluent used for 
immunodetection did not. Recently, Merza et al. (1989), 
reported that virus solubilized with 2% Triton X-100 did not 
react as well in an ELISA with neutralizing monoclonal 
antibodies directed against the F, G and H epitopes found on
gp50 as virus solubilized with Tween-20 or other non-ionic 
detergents. Since F, G and H are the primary epitopes 
towards which most cattle develop an immune response (Bruck 
et al., 1982b, 1984; Portetelle et al., 1989b), the use of a 
small amount of this non-ionic detergent in the serum 
diluent may have interferred with the ELISA. It was not 
stated if the detergent affected antibody binding via 
conformational alteration of the pertinent epitope or via 
some other mechanism of interference. It is evident that 
both the testing system used and the reagents involved in 
that system can make a big difference in the outcome of a 
particular diagnostic assay.
While the Western assay may take more time to run than 
either the AGID or the ELISA, its lack of dependency on 
detection of antibody solely to one BLV protein and its 
ability to detect animals carrying very low titers of anti- 
BLV antibodies clearly outweigh this disadvantage. Early 
detection of BLV infected cattle is a must in purebred herds 
in which overseas shipment of cattle, or embryos, to regions 
presently free of BLV is illegal if products originated from 
BLV infected herds (Thurmond and Burridge, 1982).
The proposed use of gp50 as a vaccine (Ohishi et al., 
1988; Merza et al., 1989), will necessitate the development 
of diagnostic assays that do not depend on the detection of 
gp50. The Western would be ideal in vaccination cases, as 
reactivity against gp5Q alone could readily be distinguished
from a naturally infected cow responding to various BLV 
proteins. The Western immunoassay can result in a very 
quick and effective diagnostic method for the detection of 
BLV infection.
Chapter III
Clinical and Humoral Evaluations in BLV Infected Cattle 
to BLV Structural Proteins 
Introduction
BLV is a type C exogenous retrovirus which induces 
three clinical manifestations in infected cattle: an
aleukemic stage, a persistent lymphocytotic stage and a 
lymphosarcomatous stage. Thirty to seventy percent of BLV 
infected cattle develop persistent lymphocytosis, in which 
high lymphocyte counts may stabilize for long periods, 
increase further or suddenly disappear with a return to 
normal (Burny et al., 1985a, 1987b). Less than 5% of 
infected cattle develop the lymphosarcomatous stage which 
occurs primarily in older animals (Marshak and Abt, 1967).
Although expression of BLV in vivo appears to be 
suppressed at the level of transcription (Ferrer et al., 
1980; Portetelle et al., 1981; Notzell et al., 1982; 
Kettmann et al., 1982, 1985; Burny et al., 1985a), some 
level of protein expression must occur as many studies have 
demonstrated a steady rise in antibody titer with disease 
progression (Ferrer et al., 1974; Bex et al., 1979; Kono et 
al., 1981; McGuire et al., 1981; Portetelle et al., 1981; 
Mammerickx et al., 1980; Kaaden et al., 1978; Burridge et 
al., 1982).
Although the mechanism of disease progression has not 
as yet been elucidated, serologic surveys have been
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conducted to analyze the relationship of the humoral immune 
response to BLV structural proteins and disease state. High 
antibody titers to the major gag protein, p24, of BLV have 
been associated with malignant lymphoma in cows that also 
have antibodies to the envelope glycoprotein, gp50 (Kono et 
al., 1981; McGuire et al., 1981; Thurmond et al., 1985), 
although others have demonstrated reactivity to p24 and 
other BLV structural proteins in non-LS cattle (Mussgay et 
al., 1980; Burny et al., 1980; Deshayes et al., 1980; Heeny 
et al., 1988). Most studies examined only the immune res­
ponse to the two most easily obtainable and major BLV struc­
tural proteins, gp50 and p24, however, Deshayes et al.
(1980) and Heeny et al. (1988) looked at immune responses to
all BLV structural proteins. Their similar results 
demonstrated that all sero-positive cattle reacted with gp50 
and p24, but LS cattle were more likely to possess 
antibodies that react with gp30, plO, pl2 and pl5, than sera 
from clinically "normal" cattle. Deshayes et al. (1980) at­
tributed these findings to possible quantitative differences 
in exposure to antigen. The increase in lymphocytes 
containing an integrated BLV genome ranged from 5% in AL 
cattle, 25-40% in PL cattle, and in the majority of the 
cells in LS cattle, leads one to suspect these animals would 
also have a corresponding increase in production of viral 
proteins although this association has not been proven 
(Kettmann et al., 1979, 1980a, 1980b, 1981). While most
studies have found an increase in BLV antibody levels occur 
in advanced stages of the disease (Ferrer et al., 1974; 
Portetelle et al., 1978, 1981; Bex et al., 1979; Kono et 
al., 1981; Mammerickx et al., 1980; McGuire et al., 1981; 
Thurmond et al., 1985; Heeny et al., 1988), the time these 
increased titers begin and their relationship with disease 
progression or length of time in a particular BLV disease 
state has not been established. Although many investigators 
have examined the immune response of BLV infected cattle to 
various viral proteins, few have correlated these results 
with a planned prospective study of the clinical response to 
the disease. Most investigators do not distinguish between 
the first two clinically "normal" phases of disease progres­
sion (AL and PL), or to the length of time an animal had 
been in this state when samples were taken.
In this study, clinical data was correlated with humor­
al immune responses to BLV proteins following a planned 
infection. Three novel clinical manifestations were noted 
to occur transiently during the first 16 weeks post 
infection: lymphocytosis, eosinophilia and lymph node 
enlargement. Additionally, antibody titer to the envelope 
protein, gp50, increased with time PI regardless of disease 
state. By contrast, antibodies against other viral 
proteins, pl5, pl2 and plO tended to increase early post 
infection and diminish with time PI. The most notable 
difference between AL and PL cattle was in their reactivity
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towards the gag protein, p24. The majority of the AL cattle 
developed a strong antibody response to p24 within the first 
6 weeks post infection, while PL cattle tended to have lower 
initial responses and developed increased responses to p24 
only after converting to the PL state.
Materials and Methods 
Animals and Blood Samples 
Twelve holstein heifers, 12-18 months of age, were ac­
quired from Wisconsin through the Louisiana School of Veter­
inary Medicine. Prior to entering this study all heifers 
tested negative for exposure to bovine syncytial virus 
(BSV), bovine immunodeficiency virus (BIV), anaplasmosis and 
brucellosis. In at least four separate blood samples taken 
over a nine month period, hemograms were normal and cows 
were antibody negative for BLV using the agar gel 
immunodiffusion (AGID) test (Leukassay-B, Pittman-Moore 
Inc., Washington Crossing, NJ). Cows were maintained on a 
routine vaccination (IBR, BVD, PI3) and de-worming schedule 
during the course of the experiment and at no time were 
elevated parasite burdens found in any of the heifers.
The source of the inoculum, an aged holstein donor in 
the PL stage of BLV disease, was a member of the LSU 
teaching herd and as such was on a regular de-worming and 
vaccination schedule (IBR, BVD, PI3) . She was screened and 
found negative for evidence of recent exposure to
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brucellosis and anaplasmosis using the respective card 
agglutination tests and for leptospirosis using the standard 
agglutination/lysis test. Antibody titers of less than 1:10 
were detected using an indirect immunofluorescence assay for 
IBR, BVD, PI3, and chlamydia, and a negative test for Johnes 
and Blue Tongue was run using AGID. Antibody reactivity to 
BLV was confirmed using the standard AGID test. No 
significant antibody response to BSV or BIV was detected by 
ELISA from two separate serum samples taken two weeks prior 
to and one month following her use as a BLV donor. One 
milliliter (19.6 x 106 PBL) of whole blood was used to 
inoculate each cow IV. This same animal was used in similar 
studies in which as little as 0.1ml of her blood transmitted 
BLV to recipient calves (Foil et al., 1989). Prior to, and 
following inoculation, cows were pastured in an area 
isolated from other cattle until all animals sero-converted 
as detected by AGID. Ethylenediamine-tetraacetate (EDTA) 
treated blood for CBCs and preservative free blood for serum 
samples were taken at the following intervals: once a week
for three months, once a month for three months, and once 
every two months for 18 months. Physical and/or visual 
exams were conducted at these time points to check for signs 
of lymphadenopathy. At the termination of this study, cows 
were examined rectally for the presence of enlarged lymph 
nodes that may not have been otherwise detected.
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Hematological Examination.
The number of leukocytes per microliter of whole blood 
were determined using an automated cell counter (Coulter 
model 5790). Differentials were obtained by counting 100 
leukocytes on blood smears stained with a Wright-Giemsa- 
based stain. Hematological classifications were based on 
standard criteria described by Kenyon and Piper (1977a) 
which considers an animal to be PL if it has an absolute 
lymphocyte count for three consecutive monthly bleedings 
that were greater than 2.5 standard deviations above the 
normal mean established for that animal's breed and age 
group (Kenyon and Piper, 1977a). To more accurately assess 
the lymphocyte counts above which an animal was considered 
PL, the established mean was not used, instead, the average 
of four absolute lymphocyte counts taken from each of the 12 
animals over an 8 month period prior to BLV inoculation were 
used as normal reference counts. This method was decided 
upon due to the wide variation from the mean of normal 
lymphocyte counts found between our 12 heifers prior to BLV 
inoculation. Table 5 shows the average lymphocyte count and 
standard deviation (SD) obtained for each cow. The counts 
above which an animal was classified as PL are shown in the 
last column of Table 5 (Lymph Avg + [2.5 x SD]). Similarly, 
eosinophil counts were considered elevated if they were 
greater than 2.5 x SD for the eosinophil average obtained 















Table 5. Pre-infection lymphocyte counts
# Lymphocyte Standard Lymph Avg















Fetal Lamb Kidney cells (FLK) were obtained from a lamb 
taken by cesarean section at 142 days gestation. Monolayer 
cell cultures were established using the enzymatic 
disaggregation method as described by Freshney (1983). FLK 
cells persistently infected with BLV (FLK-BLV) (Van der 
Maaten and Miller 1975a) were obtained from Dr. Van der 
Maaten (NADC, Ames IA). Monolayer cultures of each cell 
line were grown in 750 cm2 roller bottles and maintained in 
MEM containing 25mM HEPES, 10% fetal calf serum and anti­
biotics (100 IU penicillin/ml and 100 ug streptomycin/ml). 
Culture fluids were harvested every other day and stored at 
4 °C for a maximum of 48 hours. Supernates (180 ml volumes) 
were clarified at 4°C by centrifugation at 13,000 x g for 15 
min in a Sorval GSA rotor. Supernates, containing either 
virus or cell membrane fragments from the FLK-BLV and FLK 
samples respectively, were pelletted by overlaying a ten 
milliliter cushion of 20% glycerol with 190 mis of clarified 
media and centrifuging at 53,000 x g for two hours at 4°C in 
a Beckman SW19 rotor. Pellets were resuspended in 1-2 mis 
of phosphate buffered saline (PBS). The uninfected FLK 
preparation contained no known viral particles as detected 
by IFA using antisera to IBR, BVD, BT, PI-3, BRSV, BCorV, 
BRotaV, BPV, BHM, BH-3, PrV, Pseudo cowpox, CE, and 
Chlamydia psittaci. Protein concentration was determined 
using the Bio Rad microplate system (Bio Rad Laboratories,
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Richmond, CA.). Samples were frozen at -70°C in 2ral ali­
quots until needed. Solutions (100X) of BLV positive or 
negative antigen were made in PBS, aliquoted into 500 ul 
amounts and stored at -25°C until used in the ELISA assays. 
AGID/ ELISA and Western Assays for the Presence 
of BLV Antibody Reactivity 
Serum antibody responses were evaluated using three 
detection methods. The AGID was used primarily to indicate 
infection of the experimentally infected cattle. The 
progression of antibody response over time was evaluated 
using the ELISA and Western immunoassays. The ELISA assay 
was used to asses the antibody response to the partially 
purified virus, while Westerns gave us the immune response 
to individual viral proteins.
Serum samples were tested for precipitating antibodies 
to commercially prepared BLV glycoproteins using the stan­
dard AGID test. This antigen preparation contains BLV-gp50 
and a small amount of p24 (Pittman-Moore Inc., Washington 
Crossing, NJ). Test plates were incubated in a humidified 
chamber for 48 hrs before reading (Committee on Bovine 
Leukemia Virus, 1980) .
ELISA assays were run using modifications of the 
procedure described by Todd et al. (1980, 1982). Briefly, 
antigen (lOOng/well in .06M sodium bicarbonate buffer pH9.6) 
was added to 96-well Immulon (Dynatech Lab. Inc. Chantilly, 
VA.) microtitre plates and allowed to adsorb overnight at
room temperature. Nonbound antigen was removed and the 
plates were washed with one molar NaCl solution containing 
0.05% Tween 20 (wash solution). Plates were blocked for 1 
1/2 hrs with 150ul/well of 10% goat serum in PBS. Cow sera 
were diluted in serum diluent (PBS with 1M NaCl and 0.1% 
Triton X-100) at 1:50, 1:100 and 1:200, and added to the 
antigen-coated test plates. Sera were incubated at room 
temperature for 1 hr and removed by three five minute washes 
using the wash solution. Peroxidase conjugated goat anti- 
bovine IgG (H&L) (Pel-Freez, Rogers, AK) diluted 1:1000 in 
serum diluent was added, 45ul/well, and allowed to incubate 
30 minutes at room temperature. Plates were washed, and 
lOOul of enzyme substrate, (0.05M citrate buffer, pH4.0 + 
l.Omg/ml Ortho-phenylenediamine dihydrochloride [Sigma, St. 
Louis, MO.] + 0.5ul/ml of 30% H202) was added and incubated 
for 20 minutes. The reaction was stopped by the addition of 
50ul/well of 2.5M sulfuric acid. Plates were read on a 
Dynatech micro-ELISA reader at 495nm wavelength. All 
samples for individual cows were run on the same day using 
the same reagents and time intervals. Samples with high 
antibody levels and corresponding absorbance values over the 
maximum level which could be reliably detected by the ELISA 
reader were read after a 1:3 dilution with a mixture of one 
part 0.05M citrate buffer, pH4.0 and two parts 2.5M sulfuric 
acid. The resulting absorbance values were multiplied by 3 
to obtain an adjusted absorbance value (Newman et al., 1988;
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Newman, personal communication).
Each serum sample was tested in triplicate using both 
FLK and FLK-BLV antigen preparations. Multiple dilutions 
were used as titration data give more reliable measures of 
antibody quantity than absorbance values of single point 
assays. Control wells without serum (conjugate control) or 
without serum and peroxidase conjugated antibody (antigen 
control) were included on each plate. To correct for 
background caused by non-specific serum binding, the ELISA 
test results were calculated in a two step process 
incorporating methods reported by both Todd et al. (1982) 
and Florent et al. (1988). First, the absorbance value ob­
tained for the conjugate control wells on either FLK or FLK- 
BLV antigen was subtracted from the corresponding absorbance 
values obtained using the bovine serum. Secondly, the 
corrected value for serum on FLK antigen was subtracted from 
the corrected value for serum on FLK-BLV antigen to give a 
final absorbance value for reactivity to BLV for each sample 
(Figure 8). In addition to running triplicate 
samples/plate, the majority of the sera were retested at 
least once to confirm the validity of absorbance values 
obtained.
Western Blots of BLV proteins and immunodetection with 
bovine serum were run under conditions previously described 
(Chapter 2). The same crude BLV extract used for ELISA was 
separated using 12% PAGE under non-denaturing conditions,
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Correction of Absorbance Values for ELISA Data
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Figure 8. This figure demonstrates ELISA values obtained 
after correction for background non-specific binding has 
been made. (Absorbance values obtained for the conjugate 
control wells on either FLK or FLK-BLV antigen was subtract­
ed from the corresponding absorbance values obtained using 
the bovine serum.) The adjusted values for reactivity 
against FLK as antigen is shown by open circles and against 
FLK-BLV by the closed circles. The standard deviations for 
each sample are indicated.
transferred to nitrocellulose paper and allowed to react 
with the serum. All 24 samples (weeks 0 and 2-103) from one 
cow were run at the same time on nitrocellulose strips 
transferred from one gel using the same reagents and stock 
solutions. In addition to the use of molecular weight 
standards, (Sigma, St. Louis, Mo.) monoclonal antibodies 
reactive against p24 and gp51 were used as controls to 
affirm relative positions of antigen on the nitrocellulose 
strips with each set of serum samples run. Strips were also 
reacted with Con-A to confirm the glycoprotein nature of 
certain proteins (Clegg, 1982).
The density of color was used to estimate the amount of 
antibody reactivity of each sample and was analyzed using a 
Chromoscan 3 Densitometer (Joyce Loebel, England). This 
data was evaluated using the associated Joyce Loebel 
computer assisted analysis program. Linear scans were 
plotted, valley to valley background corrected, and peaks 
spotted to produce a corrected linear scan. A corrected 
linear scan for week 12 PI of cow 149, who recognized all 
the BLV structural proteins is shown in chapter 2, Figure 1. 
Due to the overlap of peaks resulting from reactivity to 
both the putative pre70ga9 and gp50, integral values 
representing the total area under a curve could not be 
calculated accurately and therefore maximum peak heights 
were used to evaluate antibody responses.
Results 
Clinical Signs
At the conclusion of this study, 103 weeks PI, 6 AL and 
6 PL cows were identified. Figures 9 - 2 0  (found in the 
Appendix) demonstrate the total WBC and absolute lymphocyte 
counts for each cow over the entire course of this study.
Of the 6 cows entering the PL stage, two became PL at 2 
weeks PI, two at 11 weeks, one at 51 and one at 68 weeks. 
Total lymphocyte counts were very variable between PL 
cattle, and within some animals over time, however, once 
diagnosed as being in the PL state, none reverted to the AL 
state (Table 6).
Three novel clinical observations were made during this 
study: transient lymph node enlargement, transient lympho­
cytosis and transient eosinophilia (Table 7). All three of 
these symptoms occurred briefly during the first five months 
PI in several cows. Moderate lymph or hemal lymph node 
enlargement of the pre-femoral, pre-scapular and cervical 
areas was observed between 8 and 12 weeks PI in half of the 
BLV infected cattle. Of the 6 cows showing this 
enlargement, 5 were AL and 1 was PL. Transient lymphocy­
tosis occurred 2-16 weeks PI in nine animals, five of which 
were AL and four were PL. The maximum cell counts observed 
were not different between the AL and PL groups. Transient 
eosinophilia was observed in 9 cattle from both the AL and 
PL stages of disease progression. The majority of the
81





93 11 High no
140 11 High yes
122 2 inter no
131 2 inter yes
123 51 inter no
132 68 low no
1Hiqh = average count > 24 x 103/ul, Intermediate > 13 x 
10 /ul and low > 9 x 103/ul 
fluctuation = changes in cell counts occuring after week 
12 PI once the PL state has been reached.
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Table 7. Kinetics of Transient Symptoms 




Eosin.1 Node Increase2 TL3
AL 76 4 — 20 12 3 - 5
86 7 - 8 10 - 11
94 11 4 - 16
99 7 - 12 2 - 12
144 9 - 16 8 - 1 2 3 - 7
149 7 — 20 10 - 12 2 - 7
PL
93 4 - 20 2 - 8
122 5 - 16
123 5 - 9 3 - 8
131
132 6 - 12 11 - 12 2 - 11
140 3 - 8
1Eosin. - Eosinophilia
increase in size of either lymph or hemal lymph nodes. 
3TL - Transient Lymphocytosis
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eosinophil increases occurred between weeks 4 - 20 PI, 
however, eosinophilia was not consistently detected during 
this time (Table 8, in appendix). Four cows had increased 
eosinophil counts at least once after the 20th week PI.
Serum Antibody Responses 
ELISA Data and Clinical Signs 
The development of antibodies to BLV over time in our 
experimentally infected cattle was initially evaluated using 
an ELISA assay system. Cows were grouped as high, 
intermediate or low responders based on their pattern of 
antibody reactivity (at 1:100 serum dilution) during the 103 
week test period. Each of these groups contained an equal 
number of AL and PL animals (Figure 2, panels A, C & E). No 
apparent differences were observed between the antibody 
reactivities of AL and PL cattle, and the majority of the 
heifers demonstrated an increase in ELISA titer over time 
regardless of clinical status. Therefore, we looked to see 
if this increase in ELISA titer corresponded to increased 
reactivity to specific proteins using a Western immunoassay. 
Western Antibody Response and Disease Progression 
Antibody responses measured by Western immunoassay 
demonstrated a wide range of reactivities to the different 
BLV proteins (Figures 3-7 and 21-27 in Appendix). The 
strongest reactions demonstrated by all cattle were against 
the envelope and core proteins gp50 and p24 respectively. 
However, moderate reactivity was also observed by all
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animals throughout the study against the envelope protein 
gp30. Less consistent responses were also observed against 
proteins with molecular weights of 162, 85, 70, 15, 12 and 
10 kd. Eight cattle also reacted to several proteins 
between 50 and 24 kd during the first 3-6 weeks PI.
Reactivity to the smaller gag proteins, pl5, pl2 and 
plO is given in Table 4. The main difference between AL and 
PL animals was in the response to plO. While neither group 
of heifers reacted with plO as often as with pl5 or pl2, 
more PL heifers showed reactivity to it and reacted over a 
longer period of time than did the AL group. In both AL and 
PL animals, reactivity against these smaller gag proteins 
was most commonly found in the first three months PI and 
diminished with time.
The overall pattern of antibody response to the major 
structural proteins, gp50, gp30 and p24, was very different 
between and within cows (Figures 28-30). Antibody 
reactivity against gp50 tended to increase over time 
regardless of disease state; however, the response to gp30 
and p24 was more variable. The most striking difference 
between AL and PL cows was found in their reactivity to p24 
(Figure 31). AL cattle tended to have a rapid increase in 
antibody response to p24 occur within the first 12 weeks PI 
followed by decreasing antibody titers, while PL cattle were 
less likely to have an initial strong peak but increased in 
their p24 reactivity after entering the PL state. However,
Antibody Response Detected by Western Immunoassay
Figures 28-30. Western immunoblots for each cow were 
scanned, peak heights measured and plotted over time PI 
for p24, gp30 and gp50.























































Comparison of Antibody Reactivity to p24 














Figure 31. The peak heights obtained on Western immunoassay for p24 were averaged 
and plotted over time.
----------  average of 5 AL cows.
----------  average of 4 PL cows which entered the PL state between 2 and 11 weeks
PI.
........ - average of 2 PL cows which entered the PL state 51 and 68 weeks PI.
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the two PL cattle which entered the PL state late PI had a 
pattern of antibody reactivity that resembled the AL cattle 
early PI and the PL cattle late PI.
Discussion 
Clinical Data 
The mechanism of disease progression following 
infection by BLV has not as yet been elucidated. In an 
attempt to define the role of humoral immune responses in 
the pathogenesis of the different BLV disease states, we 
experimentally infected 12 cattle and followed their humoral 
immune responses and disease progression. At the conclusion 
of this study, half had reached the PL stage of BLV disease 
progression, half remained AL and none had progressed into 
the LS stage. Of those that entered the PL stage, the times 
of conversion varied from 2 to 68 weeks post infection. The 
total lymphocyte counts found in these animals was also very 
variable over time in some animals, but remained fairly 
constant in others. The physiological mechanisms behind 
these wide differences in time of disease induction and in 
clinical signs of disease within the PL cattle have not as 
yet been identified.
Clinically, three novel signs were observed to occur 
transiently within the first 20 weeks PI: eosinophilia,
lymphocytosis and a moderate increase in lymph or hemal 
node size. Although these transient signs were observed in 
both AL and PL animals, the increase in lymph node size
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appeared predominantly in AL animals.
Transient eosinophilia is rarely mentioned in the 
literature, but has been reported to occur after infection 
with BLV. Seil et al. (1963), and Nobel et al. (1965), con­
firmed observations first made by Gotze (as reported in 
Straub et al., 1987a) of the presence of a transient eosino­
philia lasting less than 35 days in some BLV infected 
animals. This eosinophilia occurred prior to the lymphocyte 
increase and had returned to normal by the time the cow was 
recognized as leukotic (by one of the leukosis keys). 
Eosinophilia was thus a pre-leukosis indicator. In this 
study, its appearance seemed to be more closely related to 
time PI rather than to an impending change to the PL stage, 
as transient eosinophilia was observed in 9 cattle in both 
the AL and PL stages during the same general time interval 
PI. Cow 132 had a second episode of eosinophilia during 
weeks 59 and 68, converting to the PL stage at 68 weeks PI. 
Elevated eosinophil counts were observed intermittently over 
the entire experimental period for one AL cow. This animal 
was the "poor doer" of the group and could possibly have had 
a chronic respiratory infection that contributed to her 
eosinophilia. It appears unlikely that the elevated 
eosinophil counts were a result of parasite infestations as 
all cattle were maintained on a regular de-worming schedule 
and checked for evidence of parasites routinely throughout 
this study. While most of the increased eosinophil counts
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occurred before week 20 PI, fecals run at 16 wks PI showed 
no more than 3 EPG Trichostrongylus species in any animal 
and only 3 EPG Fasciola hepatica in 2 animals.
The transient lymphocytosis which occurred within the 
first three months PI has not been previously reported in 
the literature. However, Meiron et al. (1985), gives 
representative counts for 2 of 16 calves they experimentally 
infected with BLV. Both of these animals show a substantial 
increase in lymphocyte numbers 4-6 weeks PI. Meiron et al., 
did not give lymphocyte numbers for the other 14 calves nor 
did he mention a transient effect in his paper. In this 
study, transient lymphocytosis occurred in both AL and PL 
animals and lymphocyte counts were similarly elevated in 
both groups. Of the three cattle not showing an initial 
transient rise in lymphocyte counts, two converted to the PL 
stage at 2 weeks PI maintaining high counts from week 2 
throughout the study. The other cow without an elevated 
lymphocyte count early PI had the strongest humoral response 
as measured by ELISA of any experimental animal during this 
early time PI.
LaBelle and Conner (1964) observed enlarged hemal lymph 
nodes along the cervical vertebrae or in the paralumbar 
fossa of BLV infected cattle consistently in the early LS 
stage of disease progression. In this study, the majority 
of the cows showing mild node enlargement were AL. The only 
PL animal to demonstrate this phenomenon was the last to
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convert to the PL stage at 68 weeks PI. This suggests that 
those animals with enlarged lymph nodes also developed some 
kind of protective response inherent in disease control 
early PI.
There is apparently some proliferative response induced 
by BLV that causes this increase in node size and the number 
of lymphocytes and eosinophils. This response may be a 
direct result of the BLV pX proteins or an indirect response 
of host proteins working together with the BLV pX proteins.
The transient lymphocytosis and lymph node enlargement 
observed early after BLV infection are very similar to signs 
induced late in BLV disease progression. This leads one to 
suspect that the terminal stages of BLV infection are indeed 
due to a lack of control of certain events precipitated by 
BLV infection. These same events would occur immediately 
PI, inducing similar disease symptoms until such time as the 
immune response or other factors such as Plasma Blocking 
Factor (Gupta and Ferrer 1982; Gupta et al., 1984) can gain 
control and limit disease progression. Those animals which 
developed the node enlargement early PI may have developed 
the necessary immunity, be it humoral or cell mediated, to 
prevent a similar episode from occurring later PI. A 
breakdown in this control could then induce disease 
progression as was seen in cows 123 and 132 who converted to 
the PL state at 51 and 68 weeks PI respectively.
The mechanism inducing these transient increases are
unknown, but induction by the pX regulatory proteins is 
probable. Derse (1988), using recombinant DNA techniques 
and complementation studies demonstrated production of full 
length mRNA (9Kb) encoding the gag, prt, and RT proteins and 
singly spliced (5.1Kb) mRNA encoding env, require the ex­
pression of the pX regulatory proteins p38 and pl8, but, 
these proteins are not necessary for the production of their 
own doubly spliced 2.1Kb mRNA. Derse also demonstrated the 
proviral LTR is apparently unable to synthesize enough pl8 
or p38 to sustain self activation. Thus, in vivo, immedi­
ately after BLV infects a cell, virus transcription would 
predominantly yield the double-spliced pX mRNA, resulting in 
the subsequent low level accumulation of pl8 and p38.
Acting singly or in combination with host factors, these two 
proteins could "trans" activate B-cells resulting in 
increased lymphocyte production. Burny et al. (1987b), has 
suggested a similar mechanism for the increase of slgM on 
BLV infected B-cells via p38 "trans" activation of the Ig 
enhancer. Meiron et al. (1985) and Trainin et al. (1981) 
have shown that the total IgM level increased up to the 
fifth week PI in BLV infected calves and stayed elevated 
until around 8-16 weeks PI at which time their IgM levels 
began to decrease. Ferrer et al. (1979), demonstrated that 
in short-term in vitro cultures of BLV infected lymphocytes, 
a subpopulation of cells spontaneously incorporates 
thymidine. Because the activity of these cells could be
inhibited by sera containing BLV antibodies, he believed 
these cells may be responsive to the presence of BLV anti­
gens produced in the culture. However, these cells may be 
driven by the action of pX or similar proteins that are 
inhibited by factors present in serum, such as PBF or anti- 
pX antibodies rather than antibody to structural proteins.
In vivo, when these BLV controlling factors accumulate in 
serum, "trans" activation would be diminished, resulting in 
the decreased stimulation of cells and a return to normal 
activity. The time interval seen for the resolution of 
early transient symptoms such as lymphocytosis, node 
enlargement and elevated serum IgM levels would seem to 
correlate with the time necessary for the induction of serum 
factors or BLV antibodies in these infected animals (5-16 
weeks PI). A decrease or modification of these same factors 
may allow disease progression to occur.
Serological Data 
The serological responses to BLV proteins were 
monitored over time using AGID, ELISA and Western 
immunoassays. All BLV structural proteins were identified 
in the majority of infected cattle at some point during this 
two year study using a non-denaturing Western system. 
Antibody titer as detected by ELISA tended to increase over 
time in all animals. These titers did not correlate with 
disease state, nor did they always correlate with the 
reactivities to individual proteins as demonstrated by
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Western immunoassays. Antibody to p24 appeared first on 
Western assays in most cattle and an immediate strong 
response to p24 along with a corresponding increase in node 
size was observed in the majority of the cattle that 
remained in the AL stage.
Antibody reactivity over time was first analyzed using 
the ELISA. The ELISA assay used pelletted semipurified BLV 
as antigen. Although the exterior of the intact virus is 
covered with gp50/gp30 dimers, the virus pellet must also 
contain disrupted virions as both gp50 and p24 monoclonal 
antibodies reacted in an ELISA using the same pelletted BLV 
as an antigen source (Tables 9 & 10). Reactivity of the p24 
monoclonal antibody implies that the viral core is at least 
partially exposed in this assay and thus the ELISA could 
measure the overall immune response to all viral structural 
proteins. Although the cows fell neatly into three groups 
(high, intermediate or low responders), based on their 
antibody reactivity, no correlation of antibody response 
with disease state could be made. Most of the literature 
implies that antibody titers increase with BLV disease 
progression (Ferrer et al., 1974; Bex et al., 1979; 
Mammerickx et al., 1980; Kono et al., 1981; McGuire et al.,
1981). However, in this study, the PL cow with the highest 
WBC count was in the intermediate antibody responding group 
and a cow with one of the highest responses measured by 
ELISA was AL throughout the study. The majority of the cows
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did however, develop an increased antibody response over 
time regardless of disease state. This increase is 
apparently a function of time PI.
Because no correlation between ELISA data and clinical 
signs could be found, the Western assay was run to evaluate 
the immune response to individual viral proteins. The non­
denaturing Western assay used in this study allowed the 
detection of antibody binding to all BLV structural proteins 
(Ghysdael et al., 1979; Mamoun et al., 1983a, 1983b). The 
glycoproteins tended to produce wide bands on the gels, with 
gp50 falling between the 45-60kd range and gp30 between the 
30-35kd range, while the gag proteins produced distinct 
narrow bands.
Strong responses to the major structural proteins gp50 
and p24, and moderate responses to gp30 were found in all 
cattle tested throughout the study. Weaker reactivities to 
the smaller gag proteins, pl5, pl2 and plO, was evident in 
most cattle at some point during the experimental period.
In addition, proteins of 162, 85, and 70kd were detected in 
all cattle and a 45kd protein was detected in 10 heifers.
The presence of a 162kd protein containing 2 molecules of 
gp50/30 dimers and an 85kd protein containing one gp50/30 
dimer has been previously demonstrated on gels run under 
similar non-denaturing conditions (Mussgay et al., 1980).
We confirmed the glycoprotein nature of these high molecular 
weight proteins by reactivity with Con-A (data not shown).
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The 70 and 45 kd proteins are probably gag precursors 
(Mamoun et al., 1983b; Yoshinaka et al., 1986). Pre70989 has
been previously demonstrated in disrupted whole virus (Gupta 
et al., 1980) and the 45kd protein reacted with our anti-p24 
monoclonal antibodies (Chapter 4, Figure 36). The lack of 
reactivity of anti-p24 with the presumed pre70ga9 protein may 
be due to a conformational masking of the reactive epitope 
in the larger precursor protein which is subsequently 
revealed in the 45kd protein. Bovine serum generally 
reacted to the 45 and 70kd proteins early PI, decreased with 
time and did not correlate with disease state.
Antibody against gp50 was produced 3-10 weeks PI in all 
cattle and either increased progressively or was maintained 
at high levels in the majority of infected animals. There 
were only 2 AL animals which decreased in gp50 antibody 
reactivity after reaching peaks at 8 and 59 weeks respec­
tively. Antibody response to gp30 was usually much lower 
than reactivity to gp50, however reactivity to both proteins 
followed the same general overall pattern in 6 cattle. In 
the other 6 cows, gp30 reactivity either remained stationary 
or decreased as the anti-gp50 titer increased. Neither gp30 
or gp50 antibody responses, correlated with disease 
progression, however, gp50 reac-tivity increased over time 
PI regardless of disease progression. This increasing gp50 
antibody titer most closely correlated with similar patterns 
observed using ELISA (Figure 10) .
Antibody reactivity to p24 showed different patterns in 
AL versus PL cattle. Cattle were divided into three groups 
and their p24 antibody responses were averaged and plotted 
over time (Figure 31). The first group consisted of the 5 
AL cattle which had similar patterns of reactivity to p24. 
The PL cattle were divided into two groups, the first 
contained the four cattle that entered the PL stage between 
2 and 11 weeks PI, the second group was composed of the two 
cows that converted to the PL state late PI (weeks 51 and 
68). In the AL group, a rapid and strong increase in p24 
reactivity occurred within the first 12 weeks PI followed by 
a steady decline in p24 reactivity. In the first PL group, 
the average p24 response showed a gradual and steady 
increase over time PI. In contrast, the two cattle that did 
not enter the PL stage until 51 and 68 weeks PI had a split 
response. Their response resembled the reactivity of AL 
cattle early PI, but, after entering the PL stage of disease 
progression more closely resembled the other PL cattle.
This suggests that an initially high antibody response to 
p24 may aid in the control of disease progression. In 
contrast, the increased titer observed after the PL state 
occurs is probably a result of increased exposure to the 
presence of this particular antigen. An initially high 
titer to p24 may act to sequester BLV in a certain cell type 
or organ early PI which in turn may affect the ability to 
induce disease progression thereafter. This is supported in
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part by correlation with the clinical data concerning early 
lymph node enlargement. The five AL cattle which 
demonstrated early node enlargement were also the same five 
which had their highest reactivity to p24 early post 
infection. The only PL cow to show lymph node enlargement 
(132) had a very strong response to p24 by 3 weeks PI. This 
was higher than any subsequent response made by this animal 
until after she converted to the PL state at 68 weeks PI.
Of the smaller gag proteins identified on westerns, plO 
was recognized by more PL than AL cattle during the first 12 
weeks PI. This tends to indicate that PL cattle may be 
exposed to a wider range of viral proteins than are AL 
cattle. Reactions to p24 however, must also be considered. 
In this study, the AL cattle recognized and had an increased 
response to p24 earlier than did the PL cattle. All the gag 
proteins are supposed to be made from a common precursor, so 
one would expect the immune response to the individual 
proteins resulting from that precursor to develop similarly. 
It is interesting that during the first 12 weeks PI, AL 
cattle tended to have stronger reactions to p24 than PL 
cattle but PL and AL animals had similar responses to the 
smaller gag proteins. This same selective process occurred 
with envelope protein identification. Although both gp30 
and gp50 are produced from the same precursor protein, gp30 
antibody was elevated at times when gp50 antibody was at 
very low levels (cow 94, Figure 4). Perhaps some mechanism
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of selective processing of these protein precursors occurs 
that is different between cows. The ability to present a 
specific protein on the cell surface and subsequently 
develop an appropriate immune response may well influence 
disease progression in various animals. Cell mediated 
responses in the form of macrophage antigen presentation or 
helper-T cells may also influence this differential antibody 
response to the various viral proteins.
One must also consider the importance of the cell 
mediated immune response in those cattle that have 
efficiently controlled BLV disease progression. It is 
possible that a protective cell mediated response, with or 
without the additional influence of humoral responses such 
as that found against p24, could subsequently aid in the 
control of expression of various viral antigens and limit 
disease progression more efficiently. Cells expressing a 
particular antigen such as the pX proteins may be 
selectively destroyed by antigen specific CTL's, while cells 
expressing antigens to which a CTL response has not 
developed would trigger the increase of the humoral immune 
response to that antigen. Thus, an increase in the humoral 
immune response to proteins not necessarily involved in 
disease progression may be found. The MHC also plays a role 
in the ability of cattle to respond to individual antigens 
on a cellular basis and certain BoLa types have been 
associated with specific disease states (Stear et al., 1987;
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Burny et al., 1980). In light of this, BoLA typing was done 
on these 12 animals, but did not correlate with disease 
progression in this study (data not shown).
In summary, three novel clinical manifestations were 
observed during the first four months PI: transient 
lymphocytosis, eosinophilia and lymph node enlargement. 
Transient lymph node enlargement and temporally associated 
high antibody response to p24 was found in the majority of 
AL heifers. Some mechanism of early disease control is 
suggested. We have also shown that cows with high ELISA 
absorbance values did not necessarily identify more proteins 
on Western blots nor did they always have correspondingly 
high peak values. Similarly, antibody levels to all viral 
structural proteins did not increase over time or with 
disease progression in the first two "clinically normal" 
disease states. In fact, our data suggest that individual 
cows mount differential immune responses over time to 
proteins that are produced from the same polyprotein 
precursor. This suggests a mechanism of differential 
antigen processing, antigen recognition or both. These 
differences in antibody response and their relationship with 
disease progression must still be resolved. Likewise, the 
role of the immune response to viral nonstructural proteins, 
e.g. pX, and the cell mediated immune responses to both the 
structural and non-structural viral proteins, must also be 
examined.
Chapter IV
Cloning and Expression of Bovine Leukemia Virus gag, 
env and tax Proteins using Eucaryotic Expression Vectors.
Introduction
BLV is a type C exogenous retrovirus that is the 
etiologic agent of enzootic bovine leukosis (Deschamps et 
al., 1981). It is similar in structure, function and 
pathological signs to the human T-lymphotropic viruses 
(HTLV-I and HTLV-II) (Burny et al., 1987b; Rice et al., 
1987b; Sagata et al., 1985b). Cattle infected with BLV can 
develop three different clinical symptoms. An aleukemic 
stage in which the infected animal shows no apparent signs 
of disease, a persistent lymphocytotic stage in which the 
animal has a persistently elevated lymphocyte count but is 
otherwise "clinically normal", and a terminal 
lymphosarcomatous stage in which lymphoid tumors are 
detectable (Marshak et al., 1967; Abt et al., 1969; Burny et 
al., 1987b).
Many serologic surveys have been conducted to evaluate 
antibody responses to various viral proteins in an attempt 
to elucidate the possible mechanism of disease progression 
(Ferrer et al., 1974; Miller and Van der Maaten 1975; Bex et 
al., 1979; Deshayes et al., 1980; Mammerickx et al., 1980; 
Portetelle et al., 1981; Willems et al., 1987, 1988; Heeny 
et al., 1988). Antibody to BLV develops within 2-8 weeks 
post infection, and antibody to gp50 and p24 is present in
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all BLV infected cattle, but no direct correlation of these 
responses with disease progression has yet been made. 
Likewise, these studies have demonstrated the presence of 
antibodies against the non-structural proteins, p38 and pl8 
of BLV in LS cattle but not in "clinically normal" cattle 
(Sagata et al., 1985a; Yoshinaka and Oroszlan, 1985; Willems 
et al., 1987, 1988; Burny et al., 1987a). These proteins 
are involved in trans-activation of the viral LTR and are 
hypothesized to be involved in oncogenicity of the virus 
(Derse 1987, 1988; Burny et al., 1987b; Itohara et al.,
1988). They are produced in small quantities in the BLV 
infected cell and have a half life of less than 6 hours 
(Sagata et al., 1985a). The presence of an increased 
humoral immune response in these cattle may simply be due to 
increased antigen exposure as the number of lymphocytes 
containing the integrated provirus increases greatly during 
the LS stage.
The significance of these humoral immune responses has 
yet to be determined and their role in the prevention of 
disease progression is unclear. The protective response may 
well involve cell mediated immunity. MHC restricted, virus 
specific cytotoxic T-lymphocytes (CTL) are known to play a 
primary role in limiting viral replication and dissemination 
(Zinkernagel and Doherty, 1976). Differential killing by 
BLV antigen specific CTL's may be the major controlling 
factor in BLV disease progression. In order to develop
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reagents to further evaluate the role of the humoral and 
cell mediated immune responses to BLV proteins, we have 
cloned the gag, env and px genes of BLV into a eucaryotic 
expression vector.
Materials and Methods.
Antigen for use in the ELISA and Western assays was 
prepared from pelleted supernate of BLV infected or 
uninfected cells (Van der Maaten and Miller 1975a; Freshney, 
1983; Chapter 3). BLV purified on sucrose gradients (a gift 
from Dr. Mark Newman, Louisiana State University), was used 
in the production of monoclonal antibodies.
Monoclonal antibodies to BLV were derived from 
hybridomas by the fusion of SP2/0 cells with the spleen 
cells of BALB/c mice immunized with purified BLV using 
standard methods (Oi and Herzenberg, 1980). Initial 
hybridoma screening was conducted using an ELISA assay 
followed by indirect immunofluorescence on FLK-BLV cells and 
Western blots to determine reactivity against specific viral 
proteins. Monoclonals were also isotyped.
Isotyping was performed using a kit obtained from ICN 
immunobiologicals (Lisle, IL). Briefly, 75 ul of monoclonal 
supernates and lOul of each of six anti-sera are pipetted 
onto a precut immunodiffusion plate and allowed to incubate 
in a humidified chamber at room temperature for 24-48 hours. 
Immunoprecipitation lines relevant to the immunoglobulin 
specificity form around the appropriate well. A positive
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serum control is supplied with each kit.
The ELISA was performed after overnight adsorbtion of 
BLV antigen (100ng/50ul/well in .06M sodium bicarbonate 
buffer pH9.6) or just bicarbonate buffer alone as a negative 
antigen control to 96 well immulon microtest plates. Plates 
were blocked for 1 hr with 10% goat serum after which super- 
nates diluted 1:2 were added to the plate and allowed to in­
cubate at room temperature for 1 hr. After washing 5x with 
PBS, binding of murine monoclonal antibodies was detected 
using biotinylated goat anti-mouse IgG (Sigma, St. Louis,
MO). Avidin-biotin, horseradish-peroxidase (ABC Vectastain 
Kit, Vector Laboratories, Burlingame, CA.) was added after a 
second 5x wash step. The enzyme reaction was developed by 
the addition of 100 ul/well of the substrate solution [0.05M 
citrate buffer, pH4.0 + l.Omg/ml Ortho-phenylenediamine 
dihydrochloride (Sigma, St. Louis, MO.) + 0.5ul/ml of 30% 
H202]. The reaction was stopped by the addition of 50ul/- 
well of 2.5M sulfuric acid and absorbance at 495nm recorded 
after reading plates on an automatic ELISA reader (Dynatech 
Laboratories, Alexandria, VA.). Negative antibody control 
wells without monoclonal supernates (conjugate control), 
without supernates or peroxidase conjugated second antibody 
(antigen control) and negative mouse sera were included on 
each plate. Positive controls consisted of sera from BLV 
inoculated mice at a 1:200 dilution.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), Western transfer and 
immunodetection of viral proteins by the monoclonal 
antibodies were done using both purified and semi-purified 
BLV as antigen. Proteins (150ug purified or 700ug semi­
purified BLV) were separated on 10% gels after dilution and 
boiling at 100° for 5 min in sample buffer (0.05M Tris-HCL, 
pH 6.8 + 10% glycerol + 2% SDS + 0.1% 2-mercaptoethanol) 
essentially as described by Laemmli (1970). Samples were run 
at 4 watts per gel for approximately 4 h. For immuno­
detection, proteins were eluted from polyacrylamide gels and 
transferred to nitrocellulose paper in glycine transfer 
buffer (20 mM Tris-base pH 8.3, 150 mM glycine and 20% 
methanol) with a Trans-Blot apparatus (Bio Rad Laboratories, 
Richmond, CA) at 75 volts for 2 h (Burnette et al., 1981). 
Nitrocellulose paper was dried in a vacuum oven overnight, 
cut into strips, and washed in TBS (150 mM NaCl, lOmM Tris- 
HCL pH 7.4) for 5 minutes on a rocking platform. Strips 
were blocked for 30 min in 1% gelatin with 0.05% Tween-20 at 
room temperature. Supernates from monoclonal antibody 
producing cell lines were diluted 1:2 using blocking buffer 
and incubated with the strips for 1 1/2 h. After washing 3X 
(TBS plus 0.05% Tween-20), strips were incubated for 1 1/2 h 
in peroxidase conjugated goat anti-mouse IgG (H&L) (Sigma 
1:1000 in TBS) and washed again. This was followed by the 
addition of substrate [0.5mg/ml 4-chloro-l-naphthol (Sigma, 
St. Louis, MO.) + 5ml methanol + 25ml 0.05M Tris pH 6.8 +
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12ul 30% H202]. After 30 min, the reaction was stopped by 
rinsing the strips with distilled water. BLV negative (non­
immunized) and BLV positive (immunized) mouse sera were 
included as controls.
Indirect Immunofluorescence assays were conducted on 
cells after culture for 24-48 hours and fixing in 70% MEOH 
for 10 min. Fixed cells were blocked for 30 min with 10% 
goat serum in PBS at 37"C in a humidified chamber, followed 
by incubation for 30-60 min with monoclonal supernates 
diluted 1:2 in blocking buffer. After three five minute 
washes with PBS and a distilled water rinse, slides were 
allowed to dry. Bound antibody was detected by incubation 
with fluorescein conjugated goat anti-mouse IgG (H&L - 
Sigma, ST. Louis, MO) diluted 1:100, for 30 min, followed by 
washing and counterstaining with .05% Evans Blue. Slides 
were washed, dried and mounted using glycerol mounting 
medium and examined under a Zeiss scope equipped with a 
halogen source and epifluorescent illuminator.
Plasmids pENV-BL, pMB-SV and pBLV913, (obtained from D. 
Derse, NIH, Frederick, MD) contained the genes encoding the 
env, p38 or entire genome of BLV respectively. The genes 
encoding gag, env and p38 were removed from these plasmids 
and cloned into SV-40 based eucaryotic expression vectors 
and transiently expressed in COS-1 cells constitutively ex­
pressing the SV-40 large T antigen (Gluzman, 1981). 
Conventional recombinant DNA techniques (Maniatis et al.,
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1982) were used to transform, purify, isolate and subclone 
specific DNA fragments. Plasmid pUC-19 and Escherichia coli 
DH5a, were obtained from D.J. Messing through Bethesda 
Research laboratories. Plasmid pUC-19-Bgl is a pUC-19 
derivative containing a modification in the polylinker site 
to include a unique Bglll site immediately adjacent to the 
Sail site.
The gag gene was cloned into transient expression 
vector, P91023-B (R.J. Kaufman, Genetics Institute, Boston, 
Ma) containing the adenovirus major late promoter, 
tripartite leader sequence, VAI and VAII genes, DHFR gene 
and the SV-40 origin of replication and polyadenylation site 
(Sambrook and Gething 1988). The gag gene was removed from 
pBLV913, inserted into pUC-19-Bgl, checked for orientation, 
excised and ligated into P91023-B as follows. Insertion of 
the Sstl/BamHI fragment of pBLV913, containing the gag gene, 
into pUC-19-Bgl at the unique BamHI site required a double 
ligation procedure. First, the BamHI end of the gag frag­
ment was ligated to one of the complementary BamHI ends of 
pUC-19-Bgl which had been previously treated with calf 
intestinal alkaline phosphatase (CIAP). The remaining un­
ligated ends, BamHI (vector) and SstI (gag fragment) were 
joined after first blunting with the Klenow fragment of DNA 
polymerase I, to form pUC-19-Bgl-gag. After transformation, 
orientation was established by double digestion with 
BamHI/EcoRI. The gag fragment was removed from pUC-19-Bgl-
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gag by cutting with Bglll/EcoRI, and inserted in the correct 
orientation into the complementary cut sites of p91023-B 
(Figure 32). The BLV ENV gene was cloned by removing it 
from pENV-BL using EcoRI, and inserting it into the unique 
EcoRI site of P91023-B that had been previously treated with 
CIAP (Figure 33).
The p38 protein was cloned into transient expression 
vector, CDM8 (Brian Seed, Mass General Hospital, Harvard, 
Boston, Mass.). This vector contains both the polyoma and 
SV-4 0 origins of replication, under the control of the CMV 
promoter. In this procedure, the entire plasmid pMB-SV, 
containing the p38 gene was cloned into the CDM8 vector.
Both plasmids were cut with Hindlll, pMB-SV was treated with 
CIAP and the two plasmids ligated, to form CDM8-pUC-p38 
(Figure 34). Clones were examined for correct orientation 
by digestion with BamHI.
For transient expression of BLV proteins, gp51, p24 and 
p38, COS-1 cells were transfected with plasmid DNA using a 
procedure based on the calcium phosphate method of Graham 
and Van der Eb (1973). COS-1 cells (supplied by W. Rutter, 
University of California-San Francisco) were grown as mono­
layers in DMEM with 10% FCS, NaHC03 and antibiotics, to 50- 
70% confluency in 25 cm2 tissue culture flasks. Purified 
plasmid DNA (5-7ug) was mixed with 2.5M CaCl2 and 2xBBS [50 
mM BES, (Sigma), 280 mM NaCl, 1.5 mM Na2HP04, pH 6.95] and 
allowed to incubate at room temperature for 15-30 min.
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Medium was removed from the cells and 2ml of DEAE dextran 
(Sigma, St. Louis, MO) at 500ug/ml in Tris-buffered saline 
(TBS, 0.9% NaCl, 0.1M Tris-HCL, pH 7.4) was added for 2-3 
min at room temperature. After removing the DEAE by washing 
2x with lOmls of TBS, the DNA mixture was brought up to 5 
mis with DMEM and added to the flasks. The cells were 
incubated for 4-5 h at 37° in 5% C02, during this time, a 
fine precipitate formed over the cells. The medium and 
precipitate were removed and cells subjected to glycerol 
shock for one min (2ml of 15% glycerol in TBS). Immediately 
thereafter, 2ml of DMEM containing ImM sodium butyrate (N- 
butyric acid, Sigma, St. Louis, MO) were added and the cells 
incubated for 24 h at 37° in 5% C02. After 24 h, the cells 
were given fresh medium without butyrate and reincubated as 
above for an additional 48 h. For immunofluorescence 
assays, cells were trypsinized at 24 h post-transfection, 
reseeded into 24 well plates containing glass coverslips, 
and reincubated for an additional 48 h.
CAT assay was performed using the single scintillation 
vial method of Neumann et al. (1987) as amended by Dupont 
(1989). Cell lysates were prepared 48 h post infection 
following the procedure of Fordis and Howard (1987).
Plasmids pSV0cat and pBLH2cat were supplied by D. Derse 
(NIH, Frederick, MD) and pSV2cat was supplied by L. Schultz 
(LSU, Baton Rouge, LA) . Plasmid pSV2cat was used as a 
positive control, pSVQcat as a negative control, and pBLH2-
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cat contained the BLV LTR linked to the CAT gene.
Results and Discussion
Four monoclonal antibodies were identified which 
reacted with purified BLV (Table 9) and against partially 
purified BLV after 10X concentration (Table 10). Reactivity 
of these four monoclonals on western blots is demonstrated 
in Figure 35. Monoclonal 1.5G1-A11 and 1.5G1-D11 both 
reacted with gp50 and 1.5A6-D12 and 1.2A7-A8 recognized p24. 
All antibodies were of the IgG1 subclass.
Monoclonals A8 and D12 seemed to recognize two dif­
ferent sites on p24 as evidenced by different binding pat­
terns on Western blots (Figures 35 and 36). Antibody D12 
recognized extra bands not detected using A8. The bands 
present between 50kd and 24kd (Figure 36) may be cleavage 
products of pr70gag. Products of pr70gag identified by 
anti-p24 antibodies include pr42 gag, pr40gag and pr35gag 
(Mamoun et al., 1983a, 1983b) and pr45gag (Ghysdael et al., 
1979). Gupta et al. (1980), using gel filtration chromatog­
raphy of disrupted whole virus, demonstrated the presence of 
a 65kd protein which was the precursor of p24, pl5 and pl2. 
The presence of two bands of 28 and 26kd in addition to p24 
results when virus is stored at -20°c for long periods of 
time (Walker et al., 1987). Based on the reactivity of 
monoclonal antibody D12, we conclude that these proteins 
contain p24. Perhaps the precursor proteins are improperly 
cleaved following long term cold storage resulting in
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1:20 1: 40 1:80
1.5A6D12 1.321 1.10 .93 .69
1.2A7A8 . 08 .06 .05 .04
1.5G1D11 .31 .27 .21 .16
1.5G11A11 . 09 .05 .03 .02
1Absorbance values obtained at 495nxn. ELISA was run as 
described in text using gradient purified BLV as antigen. 
Dilutions of monoclonal supernates were made in 10% goat 
serum. Reactivity of monoclonals to negative control wells 
(bicarbonate buffer only) was less than .01 for all samples.
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1.5A6D12 l.ll1 1.02 . 912
1.2A7A8 1.18 .98 .92
1.5G1D11 .92 .78 .75
1.5G1A11 .26 .18 . 12
'Absorbance values obtained at 495nm.
2Due to the increased reactivity of 1.5A6D12 over the other 
monoclonals, all wells containing 1.5A6D12 were diluted 1:3 
before read. The reported absorbance value is therefore an 
indication of approximately one third of the actual 
reactivity of D12 in this assay. ELISA was run as described 
in text using pelletted BLV as antigen. Dilutions of 
monoclonal supernates were made in 10% goat serum.
Reactivity of monoclonals to negative control wells 
(bicarbonate buffer only) was less than .01 for all samples.
Monoclonal Antibodies Produced Against 
Bovine Leukemia Virus Proteins
Figure 35. Bovine Leukemia Virus proteins separated 
by SDS-PAGE and electrophoretically transferred to 
nitro-cellulose. Western blot reactions of 
monoclonal antibodies produced against BLV gp51 and 
p24. Anti-gp51 monoclonals are shown in lanes 1 and 
2, 1.5G1-A11 and 1.5G1-D11. Anti-p24 monoclonals are 
shown in lanes 3 and 4, 1.5A6-D12 and 1.2A7-A8. Lane 
5 shows reactivity against both proteins after mixing 



















A 8 + D 1 2  D M
Figure 36. Bovine Leukemia Virus proteins separated 
by PAGE in a native system and electrophoretically 
transferred to nitrocellulose. Western blot 
reactions of monoclonals A8+ (anti-p24 and anti gp- 
50), D12 (anti-p24) and Dll (anti-gp50). D12 demon­
strates a different pattern of reactivity than does 
A8 (A8 is anti-p24 portion of A8+) .
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production of these higher molecular weight proteins. The 
additional band at 17kd detected by antibody D12 may be from 
breakdown of p24 itself, or perhaps another fragment of the 
improperly cleaved gag precursor proteins that may result in 
the previously discussed 26 and 28 kd protein bands.
The specificity of the anti-BLV monoclonal antibodies 
for BLV proteins expressed in the cell in the native 
configuration was demonstrated using FLK or FLK-BLV cells as 
a source of negative and positive antigen respectively. The 
expression of cloned BLV structural proteins was also 
confirmed using an indirect immunofluorescence assay. The 
reactivity of the monoclonals with the transfected cell 
lines demonstrated the expression of antigenically correct 
epitopes of BLV proteins. Figure 37 shows the reactivity of 
D-12 with P9-gag and Figure 38 shows D-ll with P9-env. 
Neither monoclonal D-ll or D-12 reacted with cells 
transfected with P9-gag or P9-env respectively. This 
procedure validated both the specificity of our monoclonals 
against particular BLV proteins, and the production of 
conformationally correct BLV structural proteins.
Due to a lack of monoclonal or polyclonal antibodies 
directed against p38, we used the capability of p38 to 
transactivate the BLV LTR in the chloramphenicol acetyl- 
transferase (CAT) assay to demonstrate expression of 
functional p38 protein. Expression of CAT from pBLH2cat is 
greatly increased when co-transfected with plasmid CDM8-pUC-
Indirect Immunofluoresence of p24 in
Transfected COS-1 Cells
Figure 37. COS-1 cells transfected with p9-GAG. Gag 
protein p24 detected using D-12 (anti-p24) and indirect 
immunofluoresence.
Indirect Immunofluoresence of gp50 in
Transfected COS-1 Cells
Figure 38. COS-1 cells transfected with p9-ENV. ENV 
protein gp50 detected using D-ll (anti-gp50) and indirect 
immunoflouresence.
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p38 containing the BLV trans-acting protein. Increased 
incorporation of 14C butyl-CoA by chloramphenicol is shown 
in Figure 39. Plasmids pSV0cat and pBLH2cat had essentially 
no reactivity while pSV2cat and pBLH2cat + CDM8-pUC-p38 
showed a linear increase with time. This demonstrates the 
production of functional p38 via trans-activation of the BLV 
LTR found in plasmid pBLH2cat.
Although many studies have examined the humoral 
immune responses to BLV structural proteins, little 
correlation has been found between antibody titers and 
disease progression. Other areas must be examined to asses 
their importance in the pathogenesis of BLV disease 
induction. Of particular interest is the CMI response to 
each BLV protein as well as the humoral response to the 
ubiquitous pX proteins. This study will be simplified by 
















Detection of Expression of BLV "Trans" acting Protein 
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Figure 39. UC Butylation of Chloramphenicol by CAT.
COS-1 cells were transfected and prepared, and CAT 
assay was ran as described.
1 = pSV0cat contains the CAT gene with no promoter.
2 = pBLHjCat contains the CAT gene under the BLV 
promoter.
3 = pBLH2cat + pCDM8-p38 (double transfection) 
Production of functinal p38 "trans" activates the 
BLV promoter and increases CAT production.
4 = pSV2cat contains the cat gene under the SV40 
promoter and acts as a positive control.
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Summary and Conclusions
To use in the various assays to detect BLV, monoclonal 
antibodies against BLV envelope gp50 and gag p24 were produced 
to confirm reactivity to specific proteins for the various 
assays. To confirm reactivity of monoclonals and produce 
large amounts of selected proteins for later studies of BLV, 
the genes for env, gag, and pX were cloned into eucaryotic 
expression vectors. After transfection of appropriate 
plasmids, correct expression of cloned genes was confirmed 
using monoclonals and indirect immunofluorescence for gp50 and 
p24 and CAT assay for px.
After experimental infection with BLV, whole blood and 
serum samples were obtained from 12 holstein heifers for 103 
weeks and used to correlate clinical signs (visual observation 
and white blood cell counts) with changes in humoral immune 
response (Agar gel immunodiffusion using envelope gp50 as 
primary antigen, and ELISA and Western immunoblots using whole 
BLV as antigen). Total lymphocyte counts indicated 6 cattle 
reached the PL stage during the 103 weeks post infection (PI) . 
Cows progressed through three transient disease stages in the 
first 3 months PI: transient eosinophilia, lymph node
enlargement and lymphocytosis. Of the 6 cattle demonstrating 
early transient lymph node enlargement, 5/6 were AL. Changes 
in the humoral immune response to BLV were best detected using 
Western immunoassays. AL cattle were more likely to have an 
increased antibody response to the gag protein p24 early PI
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as compared to PL cattle. PL animals usually reached their 
highest p24 antibody responses after conversion to the PL 
stage. Antibody response to env gp50 increased as a function 
of time PI regardless of disease stage. PL cattle tended to 
recognize a greater number of the lesser gag proteins, pl5, 
pl2 and plO in the first year PI than AL cattle. All cattle 
decreased markedly in their reactivity to any of these lesser 
proteins after 51 weeks PI.
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Table 8. Changes in Eosinophil Counts Early Post Infection.
WK




122 123 132 144 149
0 0.3 0.3 0.3 1.9 1.7 1.1 0.9 1.5 1.0
1 0.7 0.4 1.1 1.3 1.2 0.5 0.2 0.8 1.4
2 1.0 0.3 0.6 1.6 1.6 0.6 0.8 0.2 0.0
3 0.7 1.1 0.4 1.1 1.3 0.9 0.6 0.5 0.6
4 3.6 0.8 1.4 1.3 1.1 0.5 0.7 1.4 0.9
5 1.3 0.7 0.6 1.4 1.9 1.7 0.9 0.4 0.8
6 2.4 0.9 1.1 1.5 3.8 0.2 1.1 1.1 0.4
7 0.5 1.9 1.9 3.3 2.6 2.7 3.7 1.5 1.6
8 1.8 1.6 0.9 2.3 2.5 2.0 0.4 1.4 0.9
9 2.4 1.1 0.9 2.8 2.6 2.6 1.2 2.7 2.2
10 0.9 0.5 1.0 2.4 2.0 0.9 0.5 1.8 2.9
11 1.4 0.7 1.0 2.2 2.5 1.1 1.4 1.4 3.1
12 2.5 0.3 0.5 2 . 3 2.8 1.3 2.1 2.8 1.8
16 1.4 0.5 0.8 1.4 2.4 1.7 0.6 2.1 2.3
20 1.3 0.9 1.1 2.1 0.9 1.3 0.7 1.2 1.8
25 0.9 0.9 0.0 1.6 0.9 0.6 0.1 1.5 1.2
H•H 1.5 1.1 2.6 U)•CM 1.7 CM•H 1.9 1.5
The nine cattle which showed increased eosinophil counts 
during the first 20 weeks post infection are listed. Counts 
above which the cow is considered to have eosinophilia 
(normal eosinophil count + 2.5 x SD) are listed in the last 
row of each column. Counts which were increased are shown 
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Figure 9. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 
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Figure 10. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples) , and once every 2 months for 
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Figure 11. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples) , once a month 
for three months (3 samples), and once every 2 months for 
















0 *1 2 3 4 3 6 7 B B 10 11 12 13 2D 23 34 43 31 39 60 71 03 B4 103
  Wee*® poBt Infection
I7~7l lymph ES I  Total WBC
Figure 12. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12* samples), once a month 
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Figure 13. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 
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Figure 14. Total White Blood Cell and lymphocyte counts for the 103 
week experimental period. Twenty five samples were analyzed. Just 
prior to experimental infection with BLV one sample was obtained (week 
0). Subsequent samples were obtained once a week for 3 months (12 
samples) , once a month for three months (3 samples) , and once every 2 
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Figure 15. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples) , once a month 
for three months (3 samples), and once every 2 months for 
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Figure 16. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 
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Figure 17. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 
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Figure 18. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 
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Figure 19. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were 
analyzed. Just prior to experimental infection with BLV one 
sample was obtained (week 0). Subsequent samples were 
obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 
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Figure 20. Total White Blood Cell and lymphocyte counts for 
the 103 week experimental period. Twenty five samples were analyzed. Just prior to experimental infection with BLV one sample was obtained (week 0). Subsequent samples were obtained once a week for 3 months (12 samples), once a month 
for three months (3 samples), and once every 2 months for 18 months (9 samples).
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Figures 21-27. Western immunoassay was run as described in 
text. Blots of antibody reactivity for cows 76, 122, 12 3, 
131, 132, 144 and 149 are given. Antibody reactivity was 
demonstrated against all the BLV structural proteins, 
although not all cows possessed reactivity to all proteins. 
The proteins shown by western include: gp50, gp30, p24,
pl5, pl2 and plO. Molecular weight markers are given on the 
left and BLV proteins identified are labelled.
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